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1.1. Epidemiology of sepsis
“Sepsis” can be summarized as the systemic response of the organism
to severe infection. Over the last decades the incidence of sepsis continues
to rise. Sepsis and its complications are the leading causes of death in
medical and surgical ICUs (Marshall J.C. et al., 1995; Tran D.D. et al., 1990)
Sepsis is a major health care problem, with a death rate that equals that
of myocardial infarction (US National Center for Health Statistics, 2001).
Sepsis is a well-documented disease process. Literature relating to its
history, incidence, risk factors (Balk R.A. 2000; Bone R.C. 1995; Zanetti G. et
al., 1997) and customized probability models using the Simplified Acute
Physiology Score II (Le Gall J.R. et al., 1995) or the Sequential Organ Failure
Assessment (Moreno R. et al., 1999) for patient outcomes contribute to our
knowledge of this complex pathological condition. ICU mortality of all sepsis
patients evaluated in three German Intensive Care Units was 35.6%. Overall
hospital mortality was 42.6%. Mean ICU length of stay (LOS) was 16.6 days.
Survivors stayed on average 4 days longer on ICU than nonsurvivors. One of
the studies focused on the epidemiology of sepsis in Germany and estimated
between 44,000 and 95,000 severe sepsis cases per year. A recently
published European epidemiological study classified 24% of infectious
patients as severely septic according to the ACCP/SCCM (the American
College of chest Physicians/Society of Critical Care Medicine) criteria (Alberti
C. et al., 2002). Severely septic patients generally require expensive
intensive care (Edbrooke D. et al., 1999; Edbrooke D.L. et al., 1999; Klepzig
H. et al., 1998). The mean direct ICU costs of care were 23297 ± 18631
Euros per septic patient and 1318 Euros per day. In comparison, average
daily charges being paid for an ICU patient by the health care system in
Germany are 851 Euros (Moerer O. et al., 2002). A recent survey conducted
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by the publicly funded Competence Network Sepsis (SepNet) reveals that
severe sepsis and/or septic shock occurs in 110 of 100,000 inhabitants
(75,000 cases/ year) and sepsis in 116 of 100,000 inhabitants (79,000 cases/
year) in Germany annually (SepNet). This illness is responsible for approx.
60,000 deaths and ranges as the third most frequent cause of death after
acute myocardial infarction. Direct costs for the Intensive Care of patients
with severe sepsis amount to approx 1.77 billion Euros. This means that
around 30% of the budget in Intensive Care is used to treat severe sepsis.
In the United States of America Angus, Derek C. MD et al. have linked all
1995 state hospital discharge records (n = 6 621559) from seven large states
with population and hospital data from the U.S. Census, the Centers for
Disease Control, the Health Care Financing Administration, and the
American Hospital Association. They defined severe sepsis as documented
infection and acute organ dysfunction using criteria based on the
International Classification of Diseases, Ninth Revision, and Clinical
Modification. Mortality was 28.6%, or 215,000 deaths nationally and also
increased with age, from 10% in children to 38.4% in patients older than 85
years. The average costs per case were 22,100 US dollars, with total annual
costs of $16.7 billion nationally. Costs were higher in infants, nonsurvivors,
intensive care unit patients, surgical patients, and patients with multiple organ
failure (Angus D.C. et al., 2001).
Padkin and coworkers analyzed the data of ninety-one adult general
intensive care units in England, Wales, and Northern Ireland between 1995
and 2000. They found that 27.1% of adult intensive care unit admissions met
severe sepsis criteria in the first 24 h in the intensive care unit. And mortality
of ICU admission with severe sepsis in the first 24 h was between 35.0%-
47.3%, and the 28-day mortality rate was 41.3%. (Padkin A. et al., 2003).
Taken together a rise of sepsis incidence during the next decades can
be expected due to the increasing use of invasive monitoring, an increase of
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antimicrobial resistance and due to the aged and immunosuppressed
population. Thus sepsis is a major health care problem now and in the future.
1.2. Definitions of Sepsis
In 1991, the American College of Chest Physicians (ACCP) and the
Society of Critical Care Medicine (SCCM) convened a “Consensus
Conference” in an attempt “to provide a conceptual and a practical framework
to define the systemic inflammatory response to infection, which is a
progressive injurious process that falls under the generalized term ‘sepsis’
and includes sepsis-associated organ dysfunction as well” (1992a). The 1992
statement from the ACCP/SCCM Consensus Conference introduced the term
Systemic Inflammatory Response Syndrome (SIRS) to describe the host
response to critical illness of either infectious or noninfectious etiology (e.g.
ischemia, pancreonecrosis, and trauma). SIRS is considered to be present
when patients have more than one of the following clinical findings:
a) Body temperature, >38°C or <36°C;
b) Heart rate, >90 min-1;
c) Hyperventilation evidenced by a respiratory rate of >20 min-1 or a
PaCO2 of <32 mm Hg;
d) A white blood cell count of >12,000 cells µL-1 or <4,000 µL-1 and
more than 10 % immature cells.
Bone et al. defined sepsis as SIRS plus infection, “severe sepsis” as
sepsis associated with organ dysfunction, hypoperfusion, or hypotension,
and “septic shock” as sepsis with arterial hypotension, despite adequate fluid
resuscitation. These general definitions are now widely used in practice and
serve as the basis for numerous clinical trial inclusion criteria.
Similarly to the TMN classification for cancer diseases (by Pierre Denoix,
1946), Levy, Mitchell M. et al. developed a classification scheme for sepsis—
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called PIRO—that stratifies patients on: √) their Predisposing conditions, √)
the nature and extent of the insult (in the case of sepsis, Infection), √) the
nature and magnitude of the host Response, and √) the degree of
concomitant Organ dysfunction (Table 1.1.). It is important to emphasize that
the PIRO concept is not extensively validated yet; extensive testing and
further refinement is needed before it can be considered ready for routine
application in clinical practice.
 Predisposition – includes all premorbid factors, which have a
substantial impact on outcome and the disease process.
Furthermore, recently genetic factors were identified to contribute to
sepsis incidence and mortality.
 Infection – the prognosis of the infection may be influenced by the
type of pathogens (strains) and the source/extent. For example, in
patients with generalized peritonitis the risk of mortality is higher than
in those with localized appendicitis. Similarly, there is a different
immune host response to gram-negative or gram-positive bacterial
invasion.
 Response – is the host immune response which is still difficult to
characterize. For quantification general symptoms and biologic
markers (procalcitonin, IL-6, TNF-α, IL-1β, and many others) may be
used (Damas P. et al., 1992; Harbarth S. et al., 2001; Hausfater P. et
al., 2002; Panacek EA et al., 1999).
 Organ – the organ failure score can be used to quantitatively
describe the degree of organ dysfunction developing over the course
of critical illness (Cook R. et al., 2001; Levy M.M. et al., 2003).
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Dynamic measures of cellular
response to insult – apoptosis,
cytopathic hypoxia, cell stress.
Response to preemptive therapy
(e.g., targeting microorganism or
early mediator) not possible if
damage already present;
therapies targeting the injurious
cellular process require that it be
present.
Table 1.1. The PIRO system for staging sepsis. TIR domain- Toll-interleukin 1 receptor.
TLR, Toll-like receptor; TNF, tumor necrosis factor; IL, interleukin; LPS,
lipopolysaccharides; SIRS, systemic inflammatory response syndrome; CRP, C-reactive
protein; PCT, procalcitonin; HLA-DR, human leukocyte antigen-DR; PAF, platelet-
activating factor; MODS, multiple organ dysfunction syndrome; SOFA, sepsis-related
organ failure assessment; LODS, logistic organ dysfunction system; PEMOD, pediatric
multiple organ dysfunction; PELOD, pediatric logistic organ dysfunction. (Levy M.M. et
al., 2003)
Human septic shock is characterized by infection and a generalized
systemic inflammatory response syndrome (SIRS) ultimately leading to
multiple organ dysfunctions (MODS) and death. (1992b; 2003) In order to
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identify the pathophysiological mechanisms involved in SIRS, including
cardiovascular decompensation, rodent models are widely used. It has been
shown in rats that an injection with bacterial lipopolysaccharides (LPS) leads
to several characteristic features of human septic shock, including febrile
responses (Klir J.J. et al., 1993; Long N.C. et al., 1990) and hypotension.
(Bauhofer A. et al., 2001)
1.3. The Immune System
The immunological host defense consists of two major parts: a) the
adaptive immunity and b) the innate immunity. The adaptive immunity exists
only in vertebrates and in phylogenetically younger animals/organisms. B-
and T-lymphocytes, responsible for the humoral and cellular immune
response are the main effectors of it. Both groups of cells express different
receptors matching specific antigens. After activation through antigen binding
they mediate proliferation and differentiation of effectors cells and so called
memory cells. Many types of receptors have been identified –most important
are the Toll-like receptors.
At present 13 different Toll-like receptor (TLR) family members are
identified (Verstak B. et al., 2007). All of them are type I transmembraneous
receptors with a similar extracellular domain, which incorporates a leucin-rich
portion (leucin-rich-repeats LRR) and a cytoplasmatic domain, which is
similar to the cytosolic part of the IL-1 receptor and is therefore called Toll/IL-
1-receptor domain (TIR), except of TLR 9 which is different. This TLR 9 is
responsible for signal transduction of bacterial DNA (Gewirtz A.T. et al.,
2001). Toll-like receptors are located in the cell membrane of the first
defense line of the immunity (such cell as macrophage, neutrophil, dendritic
and some epithelial cells). Rapidly after appearance of LPS in the blood it is
bound with high affinity to the LPS-binding protein (LBP). The complex LPS-
LBP binds to CD14 receptors expressed on the macrophage membrane
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(Ulevitch R.J. et al., 1995). Then this complex provokes an immune response
by docking to TLR4 through an adaptor molecule (Shimazu R. et al., 1999).
This docking triggers a huge release of cytokines and other mediators, which
generates the inflammatory reaction.
The innate immunity is an evolutionary old part of the immune system
which exists in plants, insects and mammals including human being. It was
initially discovered in insects which are devoid of an adaptive immune system
and rely only on innate immune reactions for their defense; this immediate
response accomplishes many activities including recognition and effector
functions. Recognition is mediated by broad specificity, pattern recognition,
receptors which recognize many related molecular structures (e.g.
polysaccharides, polynucleotides) present in microorganisms but not found in
the host. The innate responses include the release of antimicrobial peptides,
production of cytokines, acute-phase proteins, complement. This type of
immunity plays the central role in the acute phase of an infection to eliminate
pathogens. It is not an antigen specific neutralization (Janeway C.A., Jr.
1992). However, innate immunity does not induce an immunologic memory
(Medzhitov R. et al., 2000).
The strategy of the innate immune response may not be to recognize
every possible antigen, but rather to focus on a few, highly conserved
structures present in large groups of microorganisms. These structures are
referred to as pathogen-associated molecular patterns, and the receptors of
the innate immune system that evolved to recognize them are called pattern-
recognition receptors. The best-known examples of pathogen-associated
molecular patterns are bacterial lipopolysaccharide, peptidoglycan,
lipoteichoic acids, bacterial DNA, double-stranded RNA and glucans.
Although these structures are chemically quite distinct, all pathogen-
associated molecular patterns have common features (Medzhitov R. et al.,
2000). First, pathogen-associated molecular patterns are produced only by
microbial pathogens, and not by their hosts. For example, lipopolysaccharide
is synthesized only by bacteria; pattern-recognition receptors recognize
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lipopolysaccharide, thus alerting the host to the presence of the infecting
organism. Second, the structures recognized by the innate immune system
are usually essential for the survival or pathogenicity of microorganisms.
Third, pathogen-associated molecular patterns are usually invariant
structures shared by entire classes of pathogens. For example, all gram-
negative bacteria have lipopolysaccharides, and therefore, the
lipopolysaccharides pattern-recognition receptor of the host can detect the
presence of virtually any gram-negative bacterial infection (Medzhitov R. et
al., 2000).
1.3.1. Cytokines and sepsis
The systemic response to infection is mediated by the cytokines,
descended from macrophage, that target special organ receptors as a
response to injury or infection. The inflammatory response to infection or
injury is a highly conserved and regulated reaction of the organism. In case
of infection, the organism (e.g., a rat or a human being) produces soluble
proteins and lipid pro-inflammatory molecules which activate cellular
defenses, and similarly anti-inflammatory molecules are produced to
attenuate and halt the pro-inflammatory response. An overview of pro-
inflammatory and anti-inflammatory molecules is given in Table 1.2.
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Pro-inflammatory Molecules Anti-inflammatory Molecules
TNF-α Thromboxane IL-1 ra
IL-1β Platelet activating factor IL-4
IL-2 Soluble adhesion molecules IL-10
IL-6 Vasoactive neuropeptides IL-13
IL-8 (MIP-2) Phospholipase A2 Type II IL-1 receptor









MCP-1 CD14 Soluble recombinant CD-14




Table 1.2. Partial List of Pro-inflammatory and Anti-inflammatory Molecules
modified from (Bone R.C. et al., 1997) TNF= tumor necrosis factor, MIP=
macrophage inflammatory protein, MCP= monocytes chemoattractant protein,
LPS= lipopolysaccharide
Normally the cytokine response is regulated by the intricate network of
pro-inflammatory and anti-inflammatory mediators. The initial inflammatory
response is kept in check by down-regulating production and counteracting
the effects of cytokines already produced. The picture that emerges from
analysis of data from patients with sepsis is that a complex mixture of pro-
inflammatory and anti-inflammatory molecules may be present. (Dinarello
C.A. et al., 1993; Pinsky M.R. et al., 1993)
Cytokines are proteins of around 20-35 kDa. The cytokines can be
empirically divided in two groups: pro-inflammatory and anti-inflammatory.
The first cytokines are produced by TH2-lymphocytes and block activation of
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TH1-lymphocytes and macrophages. Cytokines may have multiple effects: on
neuronal signalling, in the immune defense or in wound healing, and their
function depends on various milieu factors (Hartung T. et al., 2003).
1.3.1.1. TNF – tumor necrosis factor
The name is originally derived from an observation that a soluble factor
released by macrophages after injection of LPS was able to destroy tumor
cells. Two distinct forms are described – TNF-α and TNF-β. TNF-α is a
protein of 17 kDa with 157 aminoacids. TNF-α is mostly secreted by
macrophages and TNF-β by lymphocytes. Both have similar mechanism of
action. TNF-α is involved in various sepsis mechanisms and can provoke
pyrogen reaction (via PGE2), enhances the bactericidal activity of
macrophages, can be thrombogenic, activates osteoclasts and suppresses
LPS sensitivity during sepsis (Gemsa D. et al., 1997).
1.3.1.2. IL-6 – interleukin 6
IL-6 is a 26 kDa pleiotropic glycoprotein. It influences B-cell
differentiation to plasma cells and is involved in the activation and maturation
of T-cells. Together with other interleukins IL-6 may stimulate hematopoetic
precursor cells (e.g. thrombocyte growth factor) (Ibelgaufts H. 1995). It is
released by stimulated macrophages, monocytes, fibroblasts and endothelial
cells. In acute phase reaction IL-6 is one of the main mediators. It also
stimulates ACTH synthesis; the subsequently released glucocorticoids inhibit
IL-1 and IL-6 production in a feedback loop.
1.3.1.3. IL-1 – interleukin 1
IL-1 is a polypeptide with a molecular weight of 17.5 kDa. Till now two
isoforms IL-1α and IL-1β are known with high affinity to the same receptor.
Production of IL-1 is triggered by antigens (bacteria, viruses) and LPS, as
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well as by other cytokines synthesized by macrophages, endothelial cells,
epithelial cells and B-cells. IL-1 has local and systemic effects: it activates T-
lymphocytes to produce other cytokines. IL-1 stimulates the release of
prostaglandines, complement factors and cytokines like TNF-α and
interferons by monocytes’ and macrophages’ receptor activations.
Additionally, it acts as endogenous pyrogen acting in the hypothalamic
thermoregulatory area via prostaglandin release. IL-1 production induces
simultaneously an IL-1 receptor antagonist, which counteracts IL-1effects
(Ibelgaufts H. 1995).
1.3.1.4. MIP-2 – macrophage inflammatory protein
Two murine MIP (macrophage inflammatory protein) proteins,
designated MIP-1 and MIP-2 have been described.
MIP-1 is an acidic protein, which has two variants: MIP-1α and MIP-1β
have a length of 69 aminoacids (7.8 kDa). Both MIP proteins belong to the
family of chemotactic cytokines known as chemokines. They are the major
factors produced by macrophages following their stimulation with bacterial
endotoxins. Both proteins are involved in the cell activation of human
granulocytes (neutrophiles, eosinophiles and basophiles) and appear to be
involved in acute neutrophilic inflammation (Fahey T.J., III et al., 1992; Sherry
B. et al., 1992; Widmer U. et al., 1993a).
MIP-2 is a basic protein of approximately 6 kDa. This protein is extremely
chemotactic for segmented neutrophilic granulocytes and has also a
synergistically effect in combination with G-CSF (granulocytes colony
stimulating factor) and M-CSF (monocytes colony stimulating factor). MIP-2
also induces the degranulation of human neutrophils but it does not enhance
oxidative metabolism. The two MIP-2 proteins known as MIP-2α and MIP-2β
have a high homology to each other (Sherry B. et al., 1992; Widmer U. et al.,
1993b; Wolpe S.D. et al., 1989). In man they are represented by IL-8.
18
1.3.2. Antimicrobial peptides
The activated neutrophil attacks microbes with an array of antimicrobial
peptides and proteins, including defensins and cathelicidins, which act much
like endogenous antibiotics. The term cathelicidins was introduced in 1995 to
encompass bipartite molecules containing both a cathelin domain and a C-
terminal antimicrobial peptide domain (Zanetti M. et al., 1995). Such
molecules are found in many mammals, including primates, ungulates,
rodents, and rabbits (Ritonja A. et al., 1989). Its name, an acronym for
cathepsin L inhibitor, saved its modest sequence similarity to certain
inhibitors of cysteine proteases. Although the protease-inhibitory properties of
cathelin are still unproven, the name is firmly established (Gennaro R. et al.,
2000; Zanetti M. et al., 2000). Human and murine neutrophils each contain a
single typical cathelicidin: hCAP-18 in humans and CRAMP in the mouse, but
in bovine or porcine leukocytes each contain at least 10 different cathelicidins
(Zanetti M. et al., 1995). hCAP-18 is stored in the neutrophils’ secondary
(specific) granules. The proteolytic processing that releases its antimicrobial
domain (LL-37) occurs in conjunction with its secretion, and is probably
mediated by proteinase 3 (Lehrer R.I. et al., 2002; Sorensen O.E. et al.,
2001; Zanetti M. et al., 1995).
1.3.2.1. Mechanism of antimicrobial activity
Antimicrobial activity occurs through several mechanisms (Fig. 1.1).
Interactions between the peptide and surface membranes of the target
organisms play a key role. The initial binding is thought to depend on
electrostatic interactions between the positively charged peptides and the
negatively charged molecules at the surface of the target. The biophysical
properties of the membrane are perturbed by direct interactions with the
peptide. Three main mechanisms have been suggested for peptide
permeation of the target cell membrane (van 't H.W. et al., 2001).
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1) A barrel stave mechanism involves the formation of
transmembrane channels in a voltage-dependent manner with
nonpolar domains of the molecules facing the membrane lipids
and forming a hydrophilic pore spanning the membrane (Boheim
G. 1974).
2) The aggregate channel model involves arrangement of peptides in
unstructured clusters in the membrane allowing the dynamic
formation of pores for short periods of time and the leakage of
intracellular components. Antimicrobial peptides can also enter
the intracellular space through this mechanism (Wu M. et al.,
1999).
3) A carpet-like mechanism describes covering of the microbial cell
membrane by a lawn of antimicrobial peptides (fig. 1.1.). The
integrity of the membrane collapses via holes that form by the
bending of the lipid bilayer back on itself (He K. et al., 1996; Heller
W.T. et al., 2000). Cathelicidins interact with both the inner and
outer membrane of Gram-negative microorganisms (Gutsmann T.
et al., 1999; Gutsmann T. et al., 2000). The situation for Gram-
positive bacteria is less clear; however, several Gram-positive
organisms are susceptible to cathelicidins at low concentrations
(Bals R. et al., 2003; Turner J. et al., 1998).
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Figure 1.1. Mechanisms of action of antimicrobial peptides. After electrostatic
interactions between the negatively charged bacterial wall and the positively
charged peptides (a), the peptides associate with the membranes, leading to a
destabilization of the membrane and subsequent cell death of the microorganism
(b). Several models of action have been developed (as explained in the text): b1,
barrel stave model; b2, aggregate channel model and b3, carpet model. (R. Bals
and J.et al., 2003)
21
1.3.2.2. LL-37/hCAP-18 – human antimicrobial peptide
The only known human cathelicidin LL-37 or hCAP-18 (cationic
antimicrobial peptide of 18 kDa), was isolated first from bone marrow.
(Gudmundsson G.H. et al., 1996; Larrick J.W. et al., 1995) Cathelicidins are
usually stored in the granules of neutrophils, moreover they are also
produced by various epithelial cells and keratinocytes (Agerberth B. et al.,
1995; Dorschner R.A. et al., 2001; Nilsson MF et al., 1999), monocytes, NK
cells, B cells, and γ-, δ-T cells (Agerberth B. et al., 2000), and they are
induced in keratinocytes in response to inflammatory stimuli (fig. 1.2.) (Bals
R. et al., 1998; Frohm M. et al., 1997) or injury (Dorschner R.A. et al., 2001),
as an inactive proform (cathelin-like domain C antimicrobial domain). They
undergo processing to mature peptides during or after secretion by
appropriate proteases. For example, human cathelicidin/hCAP18 is cleaved
by elastase (Gudmundsson G.H. et al., 1996) or proteinase 3 (Sorensen O.E.
et al., 2001) to liberate its C-terminal antimicrobial domain. This peptide is
called “LL-37” because it begins with two leucine residues and has 37 amino
acid residues (Agerberth B. et al., 1995; Cowland J.B. et al., 1995;
Gudmundsson G.H. et al., 1996; Larrick J.W. et al., 1994; Larrick J.W. et al.,
1995).
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Figure 1.2. Biological functions of cathelicidin antimicrobial peptides. Several cell
types secrete Cathelicidins during infection and inflammation. For example, LL-
37/hCAP-18 is found in airway surface fluid and originates from epithelial cells as
well as professional inflammatory cells, such as macrophages, neutrophils and
lymphocytes. The cathelicidin peptides have direct antimicrobial activity.
Additionally, they regulate cellular responses including cell proliferation, cell
migration of inflammatory cells, release of cytokines and angiogenesis.
Cathelicidins are multifunctional peptides that link host defense with
inflammation and angiogenesis and activate the adaptive immune system. (Bals
R. et al., 2003)
1.3.2.3. Roles of Cathelicidins in Host Antimicrobial Immunity
1.3.2.3.1. Direct antimicrobial activity. A recent study found that the
cathelin-like domain not only inhibits the protease activity of cathepsin L, a
cysteine protease, but also demonstrates potent antibacterial activity (Zaiou
M. et al., 2003). The C-terminal antimicrobial peptides of cathelicidins are
microbicidal against a broad spectrum of microorganisms, including bacteria,
fungi, and parasites, with a wide overlap in specificity, but they exhibit
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significant differences in potency from one another (Ramanathan B. et al.,
2002; Zanetti M. et al., 1995). Similar to defenses, the mechanism of
cathelicidin-mediated microbial killing depends on the formation of ion
channels or pores in the microbial cell membrane (Ramanathan B. et al.,
2002).
1.3.2.3.2. Chemotactic activity. Several cathelicidins are chemotactic for
various leukocytes. LL-37 has been found to be chemotactic for neutrophils,
monocytes (Agerberth B. et al., 2000; De Y. et al., 2000), and mast cells
(Niyonsaba F. et al., 2002). It can induce Ca2+ mobilization in phagocytes (De
Y. et al., 2000), suggesting that cathelicidins are endogenous activators of
phagocytes.
1.3.2.3.3. Induction of expression or release of inflammatory mediators.
LL-37 enhances the expression of a variety of genes by macrophages (Scott
M.G. et al., 2002). It can degranulate mast cells, leading to the release of
pro-inflammatory mediators such as histamine and prostaglandins (Agerberth
B. et al., 2000; De Y. et al., 2000; Niyonsaba F. et al., 2001). The capacity of
LL-37 to chemoattract human peripheral blood T cells (Agerberth B. et al.,
2000; De Y. et al., 2000) indicates that it can participate in the recruitment of
effector T-cells to sites of microbial infection, thereby contributing to adaptive
antimicrobial immunity.
1.3.2.3.4. Neutralization of bacterial endotoxin. Killing of bacteria by
antimicrobial peptides, phagocytes, and complement system result in the
release of bacterial components, such as endotoxin from Gram-negative
bacteria and lipoteichoic acid from Gram-positive bacteria. These bacterial
components, if allowed to enter the circulation, have a detrimental outcome
such as septic shock by inducing the production of high levels of systemic
pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6. Many of the
cathelicidins, including LL-37, SMAP-29, Bac 2A-NH2 (a linear form of Bac
2A), and indolicidin, bind LPS with high affinity and neutralize its biological
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activities (Hirata M. et al., 1994; Larrick J.W. et al., 1994; Larrick J.W. et al.,
1995; Niyonsaba F. et al., 2002; Scott M.G. et al., 2002).
1.3.2.3.5. Angiogenesis and wound healing. LL-37 can stimulate re-
epithelialization of skin wounds, and the wound repair can be inhibited by LL-
37-specific neutralizing antibody (Heilborn J.D. et al., 2003; Koczulla R. et al.,
2003; Li J. et al., 2000). Thus, cathelicidins are potentially important for
wound healing.
1.3.2.3.6. In vivo roles of cathelicidin. The participation of LL-37 in host
antimicrobial defense has been demonstrated by in vivo studies showing that
adenoviral vector–targeted systemic overexpression of LL-37 in mice results
in decreased bacterial load and mortality of experimental mice following
challenge with P. aeruginosa or E. coli (Bals R. et al., 1999b; Bals R. et al.,
1999a). Furthermore, mice deficient for CRAMP show greatly decreased
vascularization during skin wound repair (Koczulla R. et al., 2003; Yang D. et
al., 2004).
1.4. Pathophysiology of SEPSIS
The microorganisms – bacteria, initiate the pathophysiology of sepsis.
The most important components of the outer membrane are:
lipopolysaccharides – LPS, lipid A, endotoxin (in gram-negative invasion) and
lipoteichoic acid, peptidoglycan (in gram-positive invasion). Endotoxin binds
to the CD14 receptor (on the surface of monocytes, macrophages (Ulevitch
R.J. et al., 1995)). The complex CD14-LPS binds to TLR-4 which then
triggers a cytosolic cascade resulting in a release of cytokines and other
mediators. (Glauser M.P. et al., 1994; Schwandner R. et al., 1999).
Lipoteichoic acid mediates its action on cytokine release mainly via the TLR-
2 receptor (Verstak B. et al., 2007).
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1.4.1. Theory of misbalanced mediator release in sepsis
Immunomodulation is a complex, overlapping network of interactions
among factors that work together to overcome severe assaults on the body.
Unbalanced expression of them also causes SIRS and MODS. Roger Bone
has presented a hypothesis-based explanation for the apparently paradoxical
events observed in the critically ill (fig. 1.3). The five stages in the
development of multiple organ dysfunction are as follows: 1) local reaction at
the site of injury or infection; 2) initial systemic response; 3) massive
systemic inflammation; 4) excessive immunosuppression; and 5)
immunologic dissonance (Bone R.C. 1996a).
1.4.1.1. Stage 1. Prior to development of SIRS or MODS is some insult
such as a nidus of infection, a traumatic injury (including a surgical wound).
The body’s initial response is to induce a pro-inflammatory state in which
mediators have multiple overlapping effects designed to limit new damage
and to ameliorate whatever damage has already occurred. They destroy
damaged tissue, promote the growth of new tissue, and combat pathogenic
organisms, neoplastic cells, and foreign antigens. Local levels of both pro-
inflammatory and anti-inflammatory mediators can be substantially higher
than they are later found systemically (Fukushima R. et al., 1994; Meduri
G.U. et al., 1995; Puren A.J. et al., 1995).
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Figure 1.3. New concepts for the clinical sequelae of sepsis, SIRS, CARS, and
MARS. (This figure is an adaptation by Bone RC. Sir Isaac Newton, sepsis,
SIRS, and CARS. Crit Care Med 1996; 24:1125-28.)
1.4.1.2. Stage 2. If the original insult is sufficiently severe, first pro-
inflammatory and later anti-inflammatory mediators will appear in the
systemic circulation via a variety of mechanisms. The pro-inflammatory
mediators help recruit neutrophils, T cells and B cells, platelets, and
coagulation factors to the site of injury or infection. (Munoz C. et al., 1991)
This cascade stimulates a compensatory systemic anti-inflammatory
response, which normally quickly down-regulates the initial pro-inflammatory
response. The inflammatory cascade may affect organs, but significant organ
dysfunction is rare.
1.4.1.3. Stage 3. Loss of regulation of the pro-inflammatory response
results in a massive systemic reaction which induces SIRS. The
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pathophysiological changes include the following: 1) progressive endothelial
dysfunction, leading to increased microvascular permeability; 2) platelet
sludging that blocks the microcirculation, causing opportunity to provoke
ischemia, which may cause reperfusion injury and induction of heat shock
proteins; (Rinaldo J.E. et al., 1990) 3) activation of the coagulation system;
and 4) profound vasodilatation, fluid transudation may result in profound
shock (Gomez-Jimenez J. et al., 1995; Miyauchi T. et al., 1990). Organ
dysfunction or later organ failure results from these changes.
1.4.1.4. Stage 4. It is possible that a compensatory anti-inflammatory
reaction can be inappropriate, with a resulting immunosuppression -
“compensatory anti-inflammatory response syndrome” (CARS) (Bone R.C.
1996b). CARS is the body’s response to inflammation and is more than just
immune-paralysis.
1.4.1.5. Stage 5. The final stage of MODS is what we have chosen to call
“immunologic dissonance” (Kox W.J. et al., 1997). In this stage it is possible
to regain organ function if the body can recover its balance. (Bone R.C. et al.,
1997)
1.5. Temperature fluctuation – impact on sepsis
evolution
1.5.1. Hypothermia and deterioration of immune status
Animal and human studies have shown that intraoperative hypothermia
increases the risk of abnormal immune response. (Kurz A. et al., 1996;
Sheffield CW et al., 1994; Sheffield C.W. et al., 1994) Intraoperative
hypothermia is likely to cause a reduction in peripheral circulation, which may
increase tissue hypoxia and make the wound more susceptible to infection,
even if contamination levels are low. The process of warming using a warm
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air blanket, to prevent hypothermia, is becoming common practice for most
major surgery (Melling A.C. et al., 2001).
Both humoral and cellular immunity are adversely affected by lower
temperature. In bacterial infections, neutrophil chemotaxis is an essential
component of host defense. Hypothermia inhibits both neutrophil chemotaxis
and killing via the respiratory burst, and delays induction of pro-inflammatory
cytokine production by macrophages. (Kimura A. et al., 2002; Torossian A. et
al., 2003) showed that circulating levels of the cytokine interleukin-6 and the
chemokine macrophage inflammatory protein-2 were both increased with
hypothermia and ameliorated by either G-CSF administration or
normothermia. (Gropper M.A. 2003).
1.5.2. Hyperthermia – known effects in sepsis
A potential approach for the treatment of sepsis is to make use of a
natural defense mechanism called "the stress response," which is present in
virtually all-living cells. The stress response is characterized by the rapid, and
almost exclusive, synthesis of intracellular proteins known as heat-shock
proteins (HSPs). The stress response can be initiated by a wide variety of
different agents, including sodium arsenite, ischemia, several types of
metabolic stress, and exposure to a transient period of heat (Lindquist S. et
al., 1988; Nover L. et al., 1991). Some results demonstrated the protective
effects of the stress response when applied before experimental sepsis.
(Buchman T.G. et al., 1993; Buchman T.G. 1994; Rogovein T.S. 1995). And
Chu showed that heat stress applied even after the initiation of experimental
sepsis is protective against the lethal effects of sepsis. (Chu E.K. et al., 1997)
Heat stress response is an evolutionarily highly conserved response,
which is characterized by the production of heat shock proteins (Joslin G. et
al., 1991; Ribeiro S.P. et al., 1994) with high homology from worms to human
being. These proteins are proposed to have a protective role by taking part in
the cellular repair mechanism, by degradation of proteins beyond repair, and
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by altering inflammatory cellular functions (Joslin G. et al., 1991; Ribeiro S.P.
et al., 1994)). Heat stress administered before sepsis has resulted in cardiac
protection, reduction in sepsis-induced acute lung injury, and decreased
mortality in animals (Currie R.W. et al., 1993; Meng X. et al., 1996; Villar J. et
al., 1993; Villar J. et al., 1994). The mechanism of cardiopulmonary
protection by heat in sepsis is unknown but may be related to a decrease in
pro-inflammatory cytokine production (Deshpande G.G. et al., 2000).
1.5.3. The nature of heat shock proteins
Heat shock proteins (HSPs) are highly conserved proteins – chaperones
which are considered to be an immunity-regulating dangerous signal due to
their capability to induce cytokine production (Asea A. et al., 2000; Chen W.
et al., 1999; Ohashi K. et al., 2000). Chaperones are proteins involved in
repair, transport, folding, and unfolding of various intracellular proteins (Hartl
F.U. et al., 2002). It is accepted that heat stress can alter innate immune
response by inducing expression of stress proteins, such as HSPs. However,
the direct effect of heat stress on the signaling pathway that mediates innate
immunity is not clear (Zhou J. et al., 2005).
1.5.3.1. The HSP-70 family
The HSP70 family is various and mainly includes the constitutive
cytosolic Hsp70 (or Hsp73) and the stress-induced cytosolic Hsp70 (or
Hsp72). HSPs are widely believed to function as molecular chaperones.
HSPs also play important roles in antigen presentation, cross-presentation,
and tumor immunity (Wallin R.P. et al., 2002). Recently, it has been found
that HSR (heat shock response) has anti-inflammatory effects. HSPs
reduced mortality in experimental models of septic shock and adult
respiratory distress syndrome (ARDS) (Klosterhalfen B. et al., 1997; Villar J.
et al., 1994; Wallin R.P. et al., 2002), and can regulate gene expression of
pro-inflammatory and anti-inflammatory factors such as TNF-α, IL-1, IL-12,
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IL-10, and IL-18 (Snyder Y.M. et al., 1992; Tang D. et al., 2005; Wang X. et
al., 2001; Wang Y. et al., 2002).
The 70-kDa heat shock proteins (HSP70s) are expressed both
constitutively (Hsc70) and under stressful conditions (Hsp70) in all
prokaryotes and eukaryotes (Bukau B. et al., 1998). Members of the Hsp70
protein family play essential roles as molecular chaperones in the cytosol,
mitochondria, and endoplasmatic reticulum (Matouschek A. et al., 2000):
 Their levels were increased in a number of pathological
conditions (Dybdahl B. et al., 2002)
 Are required for protein translocation into endoplasmatic
reticulum and mitochondria (Matouschek A. et al., 2000)
 Are required for uncoating of clathrin-coated vesicles (Gao B.C.
et al., 1991)
 Are activators of the innate immune system (Srivastava P. 2002)
 Regulate the production of pro-inflammatory cytokines such as
TNF-α and IL-6 via CD14 and Toll-like receptor – mediated
signal transduction pathway (Asea A. et al., 2000; Asea A. et al.,
2002; Vabulas R.M. et al., 2002)
 Can be the endogenous ligand for the TLRs (Gao B. et al., 2003)
Hotchkiss et al. have reported that hyperthermia can protect mice
against lethal effects of endotoxin (Hotchkiss R. et al., 1993). Villar et al. also
reported that the induction of heat shock proteins (HSP) reduced mortality
rate and histological damage of the lung in a rat model of intra-abdominal
sepsis, produced by caecal perforation (Villar J. et al., 1994). In addition, they
showed that levels of plasma tumor necrosis factor (TNF), another important
mediator of sepsis, decreased in response to endotoxin after heat
pretreatment in rats (Ribeiro S.P. et al., 1996). Understanding the biological
consequences of fever in septic patients may be important for clinical
management. However, fever-producing cytokines, including interleukins IL-
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1, IL-6, TNF-α and interferon (IFN) - may stimulate host defense response
and regulate immune responses. Furthermore, fever induces HSP that are
known as chaperone proteins protecting essential cell components from
damage by various noxious stresses (Koh Y. et al., 1999; Lindquist S. et al.,
1988).
1.6. The CMRT (clinic modeling randomized trial)
concept
In order to investigate the effect of new immuno-modulatory drugs and
other biologic active substances a new study type for laboratory animals –
Clinic Modeling Randomized Trials – CMRT was established (Table 1.3).
Peritoneal contamination and infection (PCI) was firstly described by
Lorenz et al. (1994) (Lorenz W. et al., 1994) and validated by Bauhofer et al.
(1998) also from the Lorenz group (Bauhofer A., 1998). Analyzing
systematically the clinical situation with multiple interventions CMRTs
include: anesthesia, volume substitution, antibiotics, operation, infection with
human stool bacteria and analgesia. Further the CMRT concept was
standardized as a trial methodology for animals in analogy to the CONSORT
statement as concept for clinical trials. (Moher D. et al., 2001)
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Table 1.3. (By Torossian A., et al. Anesthesiology 2003)
Clinic modeling trials (CMRT); rationale and characteristics:
 Modeling clinical trials (scenario and methodology), before or after
conducting a clinical trial
 Modeling clinical complexity is more important than species differences
 Modeling treatment effects as expected or warranted in the clinical
scenario (δ, α and β: e.g. high sample size)
 Searching for positive and negative results
Modeling the clinical situation Modeling randomized trials
 Developed by clinicians together
with theoretical surgeon
 Adequate anesthesia (Fentanyl/
Droperidol)
 Preoperative antibiotic prophylaxis
 Perioperative volume substitution
 Operation (laparotomy)
 Peritoneal contamination with human
stool
 Outcome adapted to the clinic: high
mortality rate
 Postoperative analgesia
 Sample size calculation (δ = 0.25,
2α=0.05, 1-β= 0.9)
 Randomized allocation to the groups
 Double-blind design
 Clinically relevant endpoint (five day
mortality)
 Evaluation of morbidity
 Search for positive and negative
results
 “Intent to treat” rule
 Adequate statistical analysis
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2. Aim of the work
Despite advances in medical equipment and the administration of new
drugs for treating sepsis in intensive care units, sepsis and its consequences
remain one of the main causes of life-threatening clinical complications and is
primarily responsible for morbidity and mortality after major surgery or injury.
The human cathelicidin anti-microbial protein, hCAP18 is a component of
the innate immune system and has broad anti-microbial activity conferred by
its C-terminal fragment LL-37. The antibacterial C-terminus of hCAP18, LL-
37 (37 aminoacids), has been shown to exert a broad antimicrobial activity
upon both gram-negative and gram-positive bacteria, in order to have
synergistic antibacterial effects with the defensine, as well as to be a
chemotactic agent for neutrophile, monocytes and T cells.
Hyperthermia (induced hyperthermia) is the situation when the body is
no longer capable of sweating; core temperature begins to rise, immediately
and swiftly. It was used in cancer treatment and now we hope to see some
influence on experimental sepsis in vivo.
Recently, knowledge about a family of protective proteins seems to offer
a therapeutic or prophylactic strategy to sepsis. Since first mentioned by
Rittosa (Ritossa F. 1962), it is well accepted that living cells, from plant to
human, react to hyperthermia and other physiological or pathological
stresses by synthesizing a group of highly conserved proteins known as heat
shock proteins (HSPs). These proteins protect cells or organisms from
damage through a mechanism called thermotolerance, or cross-tolerance.
The aim of this work was a) to evaluate the effect of the anti-microbial
peptide LL-37 as addition to usual antimicrobial therapy; and b) to establish
the effect of moderate preoperative hyperthermia (41°C) alone and c) in
combination with LL-37 in the development of postoperative abdominal
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sepsis using the concept of clinic modeling randomized trials (CMRT) in rats
simulating the complex clinical situation.
We hypothesized that perioperative administration of LL-37 as a
supplement to general antimicrobial therapy and in combination with heat
stress could substantially improve the outcome of septic rats.
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3. Materials and Methods
The study was performed with permission of the local animal welfare
committee in Giessen, Hessen, Germany. The experiments were done in the
Institute for Theoretical Surgery at Philipps University Marburg, Germany.
The CMRT concept (see 1.6.) was applied in combination with the rat
peritonitis model of Peritoneal Contamination and Infection (PCI) in all trials.
3.1. Animals
All experiments were carried out in age-matched male rats. Males were
selected because they do not have estrogen cycling influences. Sex
hormones are proven to have an important influence on the outcome in
sepsis. Rats were housed under standard laboratory conditions. They were
maintained 23±1°C room temperature with 30-60% environment humidity.
Animals were kept up in Microlon-cages (dimensions: 56:34:19 cm), in one
ambiance of artificial day-night cycles (12 hour light-dark cycles).
International guidelines for animal care were followed (FELASA Working
Group on Animal Health et al., 1996). Wistar rats, 220-280g, were obtained
from Harlan-Winkelmann (Borchen, Germany) and received a standard rat
diet (Altromin R1324, Lage, Germany) and water ad libitum. The animals
were allowed to adapt to laboratory conditions for at least 3 days.
3.2. Materials and reagents for sepsis induction
3.2.1. Chemicals
- Fentanyl®, 0.05 %/ 2ml; 10 ml vials, Janssen-Cilag Ltd, Neuss
- Dehydrobenzperidol®, 25 %/2 ml; 10 ml vials, Janssen-Cilag Ltd,
Neuss
- Tramundin® 100 vials, Mundipharma GmbH, 65549 Limburg
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- LL-37, 1mg/ml (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVP
RTES-COOH) chemically synthesized in Peptid laboratory by Dr.
Henklein P. works group at the Charité, Berlin, Germany
- Metronidazole 0.5 g IV, 100 ml vials, Serag-Wiessner KG, 95119
Naila, Germany
- Cefuroxime 1500 mg IV, vials, Curasan-Kleinostheim, Germany
- Ringer’s Infusion solution, B. Braun Melsungen AG, 34209
Melsungen, Germany
- Second-glue®, UHU GmbH &Co. KG, 77813 Bühl (Baden),
Germany
- ELISA assay for cytokine determination, TNF-α, MIP-2 and IL-6
(Fa. BioSurce International, Inc., Camarillo, California, USA),
Hsp70 (Stressgen Bioreagents, 350-4243 Glanford Ave Victoria,
BC Canada V8Z 4B9)
3.2.2. Plastic and other materials
- Syringes 1 ml, 2 ml, 5 ml B. Braun Melsungen AG, 34209
Melsungen, Germany
- Microlance® 2, needle 0.55*25 mm, Becton-Dickinson S.A., Fraga
(Huesca), Spain
- Braunüle® 2.2 mm (orange), B. Braun Melsungen AG, 34209
Melsungen, Germany
- Superior® - heparin coated glass-capillars, Paul Marienfeld
GmbH & Co. KG, 97922 Lauda-Königshofen
- Falcon Tubes 16 ml, 50 ml, Genaxxon Bioscience GmbH, 88400
Biberach, Germany
- Eppendorf® -Cups, Eppendorf Vertrieb Deutschland GmbH,
50389 Wesseling-Berzdorf, Germany
- Latex gloves, NOBA Verbandmittel Danz GmbH u. Co KG.,
58300 Wetter, Germany




- ELISA reader SLT 340 ATTC ,SLT Lab Instruments, Groeding,
Austria
- SLT EasyFit – software for determination of cytokines
concentrations, SLT-Labinstruments, Crailsheim, Germany
- Infrared heating lamp 250 Watt (type –ITE; nr. 84273)
- Convection heating system INFORS – HAT (Infors AG;
Rittergasse 27, CH-4103 Bottmingen)
- Digital thermometers, Linseis Messgeraete GmbH, 95100 Selb,
Germany
- Chronometers, Linseis Messgeraete GmbH, 95100 Selb,
Germany
3.2.4. Inoculum
- Standardized human stool suspension “Mix 5”
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3.3. Preparation of stool suspension “Mix 5”
For peritoneal contamination and infection a standardized human stool
suspension was used. To obtain this suspension we took the stool from three
healthy male donors, with the aim to obtain a most similar bacterial spectrum
to induce fecal peritonitis. The stool was wrapped immediately after delivery
in plastic bags to protect the anaerobic bacteria from room air.
Immediately after collection the obtained probes were mixed carefully
with a reduced thioglycolat soup (ratio 1:1) in combination with 10% glycerin
from total weight. The reduced thioglycolate solution was prepared a day
before usage: 14.5 g thioglycolate, 50 g barium sulfate and 500 ml double
distilled water (H2O). The obtained mixture was treated with nitrogen (N2) gas
overnight to prevent further oxidation. Katalase from bovine liver was added
(0.19 mg/100ml; 2000-5000 U/mg).
The thioglycolate solution and the donors’ stool were mixed until a
homogenous mixture was obtained. The mixture was distributed in aliquots of
2, 5, 10 ml into sterile plastic cups. Then all cups were frozen at – 80°C.
This procedure was done to obtain a stool suspension for all experiments
of this project. This preparation was named “MIX5”
3.4. Study design
All trials were performed on the basis of the CMRT concept, using the rat
model of PCI. At first we determined the LD50 of the inoculum - “MIX5” and
the most effective dose of LL-37. Then we compared different administration
schedules of LL-37 in a therapeutical approach. The next step was the
investigation of LL-37 prophylaxis. And the last step was the influence of LL-
37 as prophylaxis in combination with induced hyperthermia. For each study
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and for each animal a standard protocol was used (see tab 3.1). The primary
endpoint of all trials was the 120 hour survival rate.
3.4.1. Investigations on Mix-5 and LL-37
These studies were needed to determine the LD50 of “MIX5” and the
most effective does of LL-37 for further experiments.
3.4.1.1. Determination of a dose response curve of Mix-5 in
combination with antibiotics
In this study 34 male Wistar rats were used. All of them were exposed
liable to PCI. Each group contained 8 animals. Two animals served as
reserve animals for unexpected complications before PCI if needed (for e.g.
replacement of allocated ill individuals, anesthesia complications).
Intravenous antibiotic prophylaxis was performed with cefuroxime and
metronidazole (10 mg/ 3.5 mg kg-1) applied 1 hour before and after PCI.
Mix-5 was diluted with Ringer’s solution 1:10 just before administration.
Group A (n=8) – 1.2 ml/kg inoculum
Group B (n=8) – 0.8 ml/kg inoculum
Group C (n=8) – 0.6 ml/kg inoculum
Group D (n=8) – 0.3 ml/kg inoculum
3.4.1.2. Determination of a LL-37 dose response curve
In this study 23 Wistar male rats were used. All of them were exposed
liable to PCI. Each group contained 7 animals and 2 additional animals as
reserve animals (see a.). For antibiotic prophylaxis was used cefuroxime and
metronidazole – (10 mg/ 3.5 mg kg-1). LL-37 was diluted (initial concentration
1mg/ml) with Ringer’s solution to 1:4, and administrated IV in the
corresponding dose. Administration of AMPs was done one hour before PCI
(time= -1h.)
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Group A (n=7) – control group
Group B (n=7) – 1 mg/kg LL-37
Group C (n=7) – 0.2 mg/kg LL-37
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Table 3.1. Study protocol for each animal.
Date: Group:
Study (Name)
(120 Hours surviving of animal after PCI)
Surgeon: Ear mark:
Weight:












(t = 0 h)











Anesthesia: Fentanyl 0.05 mg/ml + Droperidol 2.5 mg/ml, 3 ml/kg IP
Analgesia: Tramadol-HCl 100 µl SC
Antibiotics: cefuroxime/metronidazole 10/3 mg/kg IV 1 h for and after OP
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3.4.2. Main sepsis studies of the project
These studies follow the aim of the proposed work described previously
in Chapter 2.
3.4.2.1. Study 1 – LL-37 prophylaxis (1x) versus prophylaxis and
treatment (3x)
For this study 32 male Wistar rats were used. All of them were exposed
liable to PCI. Each group contained 10 animals plus 2 additional animals as
reserve animals (see a.). For antibiotic prophylaxis was given cefuroxime and
metronidazole – (10 mg/ 3.5 mg kg-1). LL-37 was diluted (initial concentration
1mg/ml) with Ringer’s solution 1:4, and administrated in a dosage of 0.5
mg/kg. All rats were inoculated with 0.6 ml/kg Mix-5 diluted 1:10 with Ringer’s
solution. Randomly selected, from half of the rats of each group, blood was
taken at time point t = -1h and t = +1h.
Group A (n=10) – control group
Group B (n=10) – 1x LL-37 (time t = -12h)


























Group B and C
Food depriving
A) Control group
B) LL-37 administration (12h, before OP time)
C) Three times LL-37 administration (12h, before











Figure 3.1. Prophylaxis with LL-37 1x versus 3x administration in the PCI model.
Schematic representation of the study schedule.
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3.4.2.2. Study 2 –prophylactic versus therapeutic administration of
LL-37
In this study 62 Wistar male rats were used. All of them underwent PCI.
Each group contained 20 animals plus 2 additional animals as reserve (see
a.). For antibiotic prophylaxis was used cefuroxime and metronidazole – (10
mg/ 3.5 mg kg-1). LL-37 was diluted (initial concentration 1mg/ml) with
Ringer’s solution at 1:4 and administrated IV – 0.5 mg/kg. In each group the
inoculum dose was 0.6 ml/kg, which was diluted at 1:10 with Ringer’s
solution. In half of the population of each group, blood was taken at time
point t = -1h and t = +1h.
Group A (n=20) – control group
Group B (n=20) – preoperative administration of LL-37 (time t = -12h)
Group C (n=20) – postoperative administration of LL-37 (time t = +1h)
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B) LL-37 administration (12h, before OP time)










Figure 3.2. Prophylactic versus therapeutic administration of LL-37 in the PCI
model. Schematic representation of study route.
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3.4.2.3. Study 3 – the influence of induced hyperthermia
prophylaxis in combination with LL-37 administration
In this study 90 Wistar male rats were used. All of them underwent PCI.
Each group contained 22 animals. Two additional animals were reserve
animals. For antibiotic prophylaxis was used cefuroxime and metronidazole –
(10 mg/ 3.5 mg kg-1). LL-37 was diluted (initial concentration 1mg/ml) with
Ringer’s solution to 1:4 and administrated – 0.5 mg/kg. The groups with
induced hyperthermia one day before were exposed to induced hyperthermia
for 1 hour at ~ 41°C ± 1°. The dose of inoculum for each group was 0.6
ml/kg, which was diluted at 1:10 with Ringer’s solution. In half population of
the groups, blood was taken at time point t = -1h and t = +1h.
Group A (n=22) – Control group
Group B (n=22) – 1x LL-37 (time t = +1h)
Group C (n=22) – Only hyperthermia-exposed animals (day before PCI)
Group D (n=22) – Hyperthermia-exposed animals (day before PCI) in
combination with 1x LL-37 (time t = +1h)
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Tab. 3.2. Hyperthermia protocol.
Date: . 06 .2005 Group: ____
Protocol for induced hyperthermia in rats
(24 hours before OP; ~41˚C 1 h)
Ear mark: ________









































B) LL-37 administration (1h, after OP time)
C) Hyperthermia ( 1h at 41º C; - 24h, for OP)
D) Hyperthermia ( 1h at 41º C; -24h, for OP) +




Figure 3.3. The influence of induced hyperthermia in combination with LL-37
prophylaxis in the PCI model. Schematic representation of study route.
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3.5. Conduction of the studies
Male Wistar rats, 220-280 g, (obtained from Charles River, Sulzfeld,
Germany) were assigned by simple random permutation to the study groups
using earmarks. Animals were weighed the day before the experiment and
marked with earmarks. Rats were housed under standard laboratory
conditions as described previously.
The rats were deprived of food 12 hours before operation and PCI. About
one and a half hour before surgery, all animals were anesthetized with 3
ml/kg mixture of Fentanyl 0.001% and Droperidol 2.5% (both Janssen-Cilag,
Neuss, Germany), given intraperitoneally (IP). The anesthesia dose was
calculated to maintain spontaneous ventilation. After 10-15 min (time t = -1h)
a tail vein was cannulated in anesthetized animals and an antibiotic
prophylaxis was given intraveneously, - cefuroxim and metronidazole - 10
mg/ 3.5 mg kg-1.
Before operation animals received supplemental anesthesia, with 0.1
ml/kg of anesthesia mixture. Then the animals were fixated supine on the
operation plate with adhesive strips. Using an antiseptic technique a 2 cm
(hypogastrium) midline incision was performed (hypogastrium) and 0.6 ml/kg
standardized human stool inoculum (stool concentrate diluted 1:10 in
Ringer’s solution) was injected into the pelvic region (time t = 0h) for
peritoneal contamination and infection (PCI). The inoculum dose was
established in the first study (standardization of inoculum see 3.4.1.) After
inoculum administration the wound was closed in two layers with Vicryl 3-0
suture.
One hour after operation (time t = +1) the second antibiotic application
was administered (cefuroxime and metronidazole - 10 mg/ 3.5 mgkg-1).
For postoperative analgesia, one hour after intervention (time t = +1) 20
mg/kg, tramadol was administrated s.c.
After the operation the tail vein catheter was removed and the rats were
returned to the cages single or twosome to prevent subsequent cannibalism
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of weak rats. Mortality was checked daily on two or three occasions. The
primary study end point was the 120 hours survival rate after PCI. The
survivors were sacrificed by inhalation of carbondioxide (CO2).
3.5.1. Additional interventions in the studies
AMP application: In the groups with three times administration of AMP,
LL-37 was given intravenously (0.5 mg/kg) one day before or after PCI. LL-37
was diluted (initial concentration 1mg/ml) with Ringer’s solution to 1:4. For
AMP application no additional anesthesia was performed. Animals were
fixated in a special mechanical device (Plexiglas tube) to facilitate tail vein
puncture.
Blood collection: About 1.3 ml blood was withdrawn through puncture
of venous plexus in the retro-orbital space. The puncture was done with
heparin coated glass capillaries and collected in 2 ml Eppendorf cups. Blood
sampling was performed always under anesthesia. Each blood sample
withdrawn was substituted by IV application of about 2 ml Ringer’s solution.
Hyperthermic preconditioning: One day before PCI the hyperthermia
groups were subjected to induced hyperthermia. Before the procedure all
animals were anesthetized with intra-peritoneal (IP) administration of fentanyl
and droperidol (the same dose and mixture as above). About 15 min after
anesthesia animals were placed under an IR (infrared) heating lamp. A digital
thermometer was inserted 2-3 cm into the rectum for continuous core
temperature measurement throughout the heating period. When the core
temperature reached 40° - 40.3°C (approx. after 10-12 min) animals were
placed for one hour in a convection heating box “INFORS – HAT” to adjust to
the desired temperature. After another 8-10 min the core temperature
reached 41°C ± 0.6°C. The elevated body temperature was maintained for
one hour. Then the animals were transferred to room temperature and 3 ml
of Ringer’s solution were injected subcutaneously (s.c.) for rehydration. After
the heating procedure animals were housed under standard conditions.
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3.6. Bioassays – ELISAs
For systemic cytokine analysis blood was collected at two time points of
the experiments: “-1h” – one hour before OP (before the first antibiotics
administration), “+1h” – one hour after OP (before the second antibiotics and
LL-37 administration). For blood collection heparin-coated glass-capillars
were used. About 1.3 ml blood was collected, eppendorf tubes were placed
in water/ice bath at ~ 0°C and centrifuged at + 4°C for 10 min at10.000 x G.
The obtained plasma was transferred into new eppendorf cups and
immediately frozen at – 40°C till analysis.
We have determined the following parameters: TNF-α, MIP-2, HSP70
and IL-6. Each assay contains 96 vial standard plates for ELISA reader
analysis. The measurements were done with a SLT 340 ATTC ELISA Reader
at a wave length of 450 nm and the calculations were performed with the SLT
EasyFit software. Measurements were performed as described in detail in the
ELISA-kit booklets of the manufacturer.
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3.7. Statistical evaluation
The primary endpoint was the 120-hour survival rate. The sample size
was calculated with the formula of Friedman et al. (Friedman L.M. et al.,
1985) estimating a treatment difference in the mortality rate of 20-50% (δ =
0.2-0.5), an α-error of 0.025 and a power of the test 1-β = 0.9. During the
course of the experiments we decreased the delta (δ = 0.2), which resulted in














N – total sample size (subjects) with   2/21  
Zα – the critical value witch corresponds to the significance level α
Zβ – the value of the standard normal value not exceeded with probability β
p1 – the event rates in the first intervention group and
p2 – in the second group
(Friedman L.M. et al., 1985)
Mortality rates were analyzed with the Chi-square test. Kaplan-Meier
survival curves were plotted and analyzed with the log-rank test. Cytokine
data were analyzed with the non-parametric Kruskal-Wallis ANOVA-Test.
Only in the case of significant results in the global test, post-Hoc-Tests were
performed including a Boferroni correction. All performed tests were analyzed
using the SPSS statistic software package for windows (Bühl A. et al., 2000).
Cytokine data were given as mean ± SEM (standard error mean). P levels
below 0.05 were considered as significant in all tests used.
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4. Results
4.1. Results of preliminary studies
4.1.1. Dose response curve of inoculum MIX-5
In this study the LD50of “MIX5” was determined. A standard dose of the
antibiotics, cefuroxime and metronidazole 10 /3.5 mg/kg respectively was
administered with a variable dose of the “MIX5” suspension. Four groups of 8
animals each were investigated with dosages of 1.2; 0.8; 0.6; 0.3 ml/kg in a
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Figure 4.1.1. MIX-5 dose response curve
With a concentration of 1.2 ml/kg no rat survived. A concentration of 0.8
ml/kg resulted in a mortality below the LD100 with 13% survivors. Further
reductions of the inoculum quantity up to 0.6 ml/kg led to a survival of 50 %.
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On a concentration of 0.3 ml/kg all animals survived. The LD50 of MIX-5 (0.6
ml/kg) was used for all further experiments.
4.1.2. LL-37 dose response curve
The application schedule of LL-37 was optimized in combination with the
antibiotics (cef/met). With the LD50 dosage of “MIX5” we investigated two
different dosages of LL-37. The animals were exposed to the same treatment
as in previous experiments. In addition, at the first antibiotic administration
(-1h, before OP) LL-37 was IV injected in a dosage of 0.2 and 1 mg/kg. The
antibiotic administration was in the same amount as described before. The
control group received the same treatment without antimicrobial proteins (see















Figure 4.1.2. Survival of rats after prophylactic LL-37 application
Unexpectedly, in the low concentration group of 0.2 mg/kg LL-37 all rats
survived. In the high dose group with 1 mg/kg LL-37 a mortality of 29% was

























Figure 4.1.3. 120h Kaplan-Meier survival analysis of rats comparing different
doses of LL-37 in septic rats, p= 0.069 df 2 in Log Rank test (n=7/group)
We achieved a survival rate of 100% in the 0.2 mg/kg group. However in
the 1 mg/kg group survival was with 71% better as in the control group; and
without significance in the Kaplan-Meier survival analysis (Figure 4.1.3., Log
Rank Test p=0.069, df=2). Based on our results and findings of others
(Cirioni O. et al., 2006), we used for further experiments a concentration of
0.5 mg/kg LL-37.
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4.2. Survival rates in the main studies
4.2.1. LL-37 prophylaxis (1x) versus prophylaxis and
treatment (3x)
The groups were homogenous; mean body weight was 250 ± 30 g. All
animals were included in the data analysis.
In the control group we achieved a survival rate of 40%. In the group with
antimicrobial protein LL-37 prophylaxis, administrated -12h before PCI
survival was increased to 70%. In the group with antimicrobial protein LL-37
administrated three times (at -12h; +12h; +36h in relation to PCI), the survival
rate was 67% (figure 4.2.1.). Both groups were not significantly different from



















Figure 4.2.1. Survival rate (120h) of rats after: “Control” - PCI without prophylaxis; “-
12h LL 1x” - PCI with antimicrobial protein (AMP) LL-37 (0.5 mg/kg) administrated
i.v. 12h before contamination; “LL 3x” - PCI with antimicrobial proteins (AMPs) LL-37


























Figure 4.2.2. Kaplan-Meier survival analysis of rats comparing LL-37 prophylaxis
1x versus prophylaxis and treatment 3x with control in septic rats over 120h.
Peritoneal contamination and infection (PCI) was performed with standardized
human stool.
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4.2.2. Prophylactic versus therapeutic administration of
LL-37
The groups were homogenous; all animals had a similar body weight of
250 ± 30 g. All animals were included in the data analysis.
We achieved a survival rate of 30% (6/20) in the control group. In the
group with antimicrobial proteins (AMPs) LL-37 prophylaxis at 12 hours
before contamination, survival was increased up to 55% (11/20). But only
PCI with antimicrobial proteins (AMPs) LL-37 administrated i.v. one hour after
contamination, (therapeutic administration) was able to improve survival after
PCI significantly up to 70% (14/20) (fig. 4.2.3.) (p= 0.0038, df =2; LL-37





















Figure 4.2.3. Survival rate (120h) of rats after: Control - PCI without prophylaxis;
“-12h LL 1x” - PCI with antimicrobial proteins (AMPs) LL-37 administrated IV one
times 12h before contamination; “+1h LL 1x” - PCI with antimicrobial proteins



























Figure 4.2.4. Kaplan-Meier shows survival analysis of rats comparing LL-37
prophylactic versus therapeutic administration with control group in septic rats
over 120h. Peritoneal contamination and infection (PCI) was performed with
standardized human stool, AMP was administered in 0.5mg/kg concentration.
Statistical analysis reveals a significant difference in the Log Rank test between
“+1h LL 1x” and “Control” p=0.012, df1, as well in χ2 (Chi2) test p<0.01, df1.
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4.2.3. The influence of induced hyperthermia prophylaxis in
combination with LL-37 in the PCI model
The groups were homogenous with a similar weight of 250 ± 30 g.
The survival in this experiment was 64% (54/84) at 120 hours (end point
of experiment) after peritoneal contamination and infection (PCI). We
achieved a survival rate of 38% (8/21) in the control group. Hyperthermia
(day before PCI at 41°C during 1 hour) alone improved the survival rate up to
59% (13/22). Approximately the same improvement in the survival rate was
obtained with antimicrobial proteins (AMPs) LL-37 administrated IV ones one
hour after contamination; survival was slightly increased up to 67% (14/21).
Only the combinatory group hyperthermia plus LL-37 was able to improve the
survival rate significantly to 90% after PCI (19/21) (figure 4.2.5.). LL-37
therapy combined with hyperthermic preconditioning improved the survival
rate versus control: p = 0.001, df 1; versus hyperthermia alone p=0.02;
versus LL-37 therapy p=0.08 in the χ2 (Chi2) - test. Furthermore the Kaplan-
Meier survival analysis revealed significant differences over all groups p=
0.01, df=3 in the Log Rank test and a significant difference between control
group and hyperthermia in combination with LL-37 administrated IV once. In























Figure 4.2.5. Survival rate (120h) of rats after: “Control” - PCI without prophylaxis
(n=21); “+1h AMP 1x” - PCI with antimicrobial proteins (AMPs) LL-37
administrated IV one times 1h after contamination (n=21); “Hyperth” - induced
hyperthermia in rats 24 hours before PCI at 41°C during 1 hour (n=22); “Hyperth
- +1h AMP 1x” - induced hyperthermia in rats 24 hours before PCI at 41°C
during 1 hour in combination with PCI with antimicrobial proteins (AMPs) LL-37


























Figure 4.2.6. Kaplan-Meier survival analysis of rats comparing induced
Hyperthermia versus AMP once one hour after contamination versus induced
Hyperthermia in combination with AMP administration ones one hour after
contamination with control in septic rats over 120h. Peritoneal contamination and
infection (PCI) was performed with standardized human stool, AMP (LL-37) was
administered in 0.5 mg/kg concentration. Induced hyperthermia was performed
24 hours before PCI at 41°C during 1 hour. Statistical analysis reveals a
significant difference in the Log Rank test between “Hyperth +1h LL 1x” and
“Control” p=0.001, df1, as well in χ2 (Chi2) test p<0.01, df1.
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4.3. Cytokine expression in the studies
4.3.1. Levels of cytokines after LL-37 administration
In all trials the basal level (before PCI) of the plasma cytokines IL-6,
TNF- and the chemokine MIP-2 were at the detection limit of the assays.
One hour after PCI they increased in the plasma of the rats.
The ONEWAY ANOVA test for TNF- revealed a high significance of p
0.001, df7. Increasing TNF- levels were expected in the control group after
PCI compared to the control group before PCI (p 0.05), df1. Prophylactic
administration of LL-37 before PCI did not change the increase of TNF-
after PCI (p 0.05, df1). Changes in other groups were not statistically
significant in Post-Hoc tests. (Fig. 4.3.1.)
Data obtained from different groups one hour before PCI were pooled
since animals were treated identically. In comparison to TNF-, MIP-2
showed more statistical significant differences. In the ONEWAY ANOVA test
the significance was obtained at a level of p 0.001. A visual comparison of
the two cytokines obtained the same tendency of increase after the same
intervention. The post-hoc test showed significance between “Control -1h”
and “Control +1h” p0.05. Subsequent significant results were obtained with
the Post-Hoc test (df =1): “Control -1h” *p  0.001 versus “-12h AMP +1h”; #
p  0.05 “Control +1h” versus “+1h AMP 1x +1h”; ^ p  0.05 “-12h AMP -1h”
versus “-12h AMP +1h”; *p  0,001 “+1h AMP 1x -1h” versus “-12h AMP
+1h”. (Fig. 4.3.2.)
For IL-6 determination we did not have enough plasma to analyze all
experimental groups. In addition, in more than half of the samples in which
IL-6 measurement was possible the levels were at the detection limit of the






























Figure 4.3.1. Value of TNF- of septic rats with LL-37administration. Peritoneal
contamination and infection (PCI) was performed with standardized human stool,
LL-37 was administered in a dose of 0.5 mg/kg. Statistical analysis reveals a
significant difference in the ONEWAY ANOVA test p=0.001, df7. Post-hoc test:
p=0.024 “Control +1h” vs. “Control -1h” and p=0.011 “-12h LL +1h”versus “–12h


























Figure 4.3.2. Value of MIP-2 in AMPs experiments, with control in septic rats
over 120h. Peritoneal contamination and infection (PCI) was performed with
standardized human stool, AMP was administered in 0.5 mg/kg concentration.
Statistical analysis reveals a significant difference in the ONEWAY ANOVA test
p0.01. The data are expressed as means  SEM.
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4.3.2. Cytokines and HSP determination in animals with
induced hyperthermia in combination with LL-37
administration
The global statistical test ONEWAY ANOVA demonstrates a moderate
significance (p 0.05, df 5). Postoperative levels of TNF- in the control
group were increased but with no statistical significance. We can see a
tendency (p=0.087, df 1). In other postoperative groups is noted a tendency
to diminish the TNF- plasma levels. The Post-Hoc Boferroni test shows no
significance between the groups. The highest postoperative diminishing of
TNF- is noted in the last group “Hyperth +LL 1x +1h”. (Figure 4.3.3.)
Preoperative MIP-2 plasma concentration was at the detection limit of
the assay. The ONEWAY ANOVA test for MIP-2 was p 0.001, df 5.
Subsequent Post-Hoc tests (Boferroni) revealed following results: between
“Control -1h” and “Control +1h” p 0.001, df 1; “Control +1h” and “Hyperth
+1h” p  0.05, df 1; “Control +1h” and “Hyperth +LL 1x +1h” p 0.05, df 1. In
the both hyperthermia groups almost the same postoperative plasma levels
were determined, showing a significant reduction of the chemokine MIP-2 in
comparison with postoperative levels of the control group. (Figure 4.3.4.)
In comparison with TNF- and MIP-2, IL-6 has approximately the same
levels and showed the same statistical tendency. A performed ONEWAY
ANOVA test demonstrates a significance of p 0.001, df 5. And with the Post-
Hoc Boferroni test we have obtained p 0.005, df 1 between “Control -1h”
and “Control +1h”; and the next statistical significance was p 0.005 in
“Hyperth +LL 1x +1h” with “Control +1h”. Postoperative plasma levels of IL-6
out of control group had decreasing concentration direction, so in the
“Hyperth +LL 1x +1h” the minimal plasma level was depicted. (Figure 4.3.5.)
HSP-70 levels were in the most samples below the detection limit. For
















Figure 4.3.3. Value of TNF  in induced hyperthermia in combination with AMPs,
with control in septic rats over 120h. Peritoneal contamination and infection (PCI)
was performed with standardized human stool, AMP was administered in 0.5
mg/kg concentration. Statistical analysis reveals a significant difference in the




















Figure 4.3.4. Value of MIP-2 in induced hyperthermia in combination with AMPs,
with control in septic rats over 120h. Peritoneal contamination and infection (PCI)
was performed with standardized human stool, AMP was administered in
0,5mg/kg concentration. Statistical analysis reveals a significant difference in the
ONEWAY ANOVA test p0,001. In Post-Hoc Boferroni test “Control -1h” and
“Control +1h” p 0.001, df 1; “Control +1h” and “Hyperth +1h” p  0.05, df 1;
“Control +1h” and “Hyperth +LL 1x +1h” p 0.05, df 1. The data are expressed


















* p=0.004 vs 1.
#p=0.015 vs 2.
Figure 4.3.5. Value of IL-6 in induced hyperthermia in combination with AMPs,
with control in septic rats over 120h. Peritoneal contamination and infection (PCI)
was performed with standardized human stool, AMP was administered in 0.5
mg/kg concentration. Statistical analysis reveals a significant difference in the
ONEWAY ANOVA test p0,001. In Post-Hoc Boferroni test p 0.005, df 1
between “Control -1h” and “Control +1h”; and the next statistical significance was




Endotoxemia and shock can occur during antibiotic therapy of sepsis
caused by the release of LPS from the outer membrane of destroyed bacteria
(Kirikae T. et al., 1997; Shenep J.L. et al., 1985). Once released, the
biological activity of LPS is difficult to be neutralized. Thus, a substance that
suppresses the actions of LPS could be a reasonable adjunct for preventing/
treating endotoxin shock or sepsis caused by Gram negative bacterial
infections. Several substances, including neutralizing antibodies against LPS,
LBP (LPS binding protein), or cytokines, have been tested to prevent the
cascade of LPS-induced hyper inflammation (Le Roy D. et al., 1999).
However, much attention has recently been focused on low molecular-
weight cationic antibacterial peptides that possess both antibacterial and
LPS-neutralizing activities. Originally, these peptides were shown to
contribute to the host’s innate defense system against microbial infections by
impairing the membranes of targeted organisms (Gudmundsson G.H. et al.,
1999; Hancock R.E. et al., 2000a). Recently, it was reported that a peptide
derived from human LL-37, one of the cathelicidin family, could lower serum
TNF-α levels and protect mice from lethal endotoxin shock (Kirikae T. et al.,
1998). Our results suggest that LL-37 can prevent sepsis, especially in higher
doses. Even in lower doses, overall assessment scores improved. On the
other hand, higher doses for treating sepsis appeared to have adverse
effects and appeared to be toxic to organs (especially cytotoxic) affected by
sepsis (Fukumoto K. et al., 2005). Therefore, lower doses of LL-37 can be
used to treat sepsis, but higher doses should not be used. This paradox may
arise because LL-37 seems to be able to damage the cells of a septic organ
directly. At lower doses, its inhibition of LPS-induced TNF-α expression is
stronger than any direct damage it causes, but at higher doses the inhibitory
action is overridden by the direct damage activity. This is only a hypothesis at
present and needs further study to elucidate the exact mechanism involved.
From our study, we conclude that the safest use of LL-37 for both prevention
and treatment is at lower doses. A dose of 1 mg/ml LL-37 seems to be
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already too high, since with this dose a higher mortality was obtained
compared to a dose of 0.2 mg/ml. Rats given the highest doses actually died
before the rats with the lowest doses did, so higher-dose of LL-37 would
appear to be toxic through a mechanism as postulated by Ciornei et al.
(Ciornei C.D. et al., 2005; Ciornei C.D. et al., 2006). Further study to
determine the safest dose is required before LL-37 can be used clinically
(Fukumoto K. et al., 2005).
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5.1. Implication of LL-37 in infectious disease - sepsis
Antimicrobial peptides play an important role in innate immunity by acting
as effector molecules in host defenses against pathogens. The dominating
targets are bacterial membranes, and the killing reaction must be faster than
the growth rate of the bacteria. Antimicrobial peptides (AMPs) have emerged
as multifunctional effector substances of the innate immune system.
The role of antimicrobial peptides as effectors of innate immunity is
widening from solely endogenous antibiotics to multifunctional mediators that
provide a first line of host defense, modify the local and global inflammatory
response, and activate some immunological mechanisms (Boman H.G. 2003;
Hancock R.E. et al., 2000b; Zanetti M. 2004). Previously, researches showed
that LL-37 is a potent immune modulator and that it stimulates the expression
of a wide variety of genes involved in the innate immunity. It has been
demonstrated to be a chemoattractant for human monocytes, T cells, and
mast cells. Furthermore, LL-37 is a potent anti-endotoxic agent and induces
chemokine production. It also has a variety of other functions, including
promotion of histamine release from mast cells, inhibition of tissue proteases,
stimulation of wound healing and angiogenesis (Bowdish D.M. et al., 2004)
AMPs are part of the innate immune system of many species and are
thought to provide protection against bacteria, fungi and viruses, either by
directly killing or binding to bacterial endotoxin and blunting the biological
effects of infection (Lehrer R.I. et al., 1999). It has been shown previously
that systemic administration of peptide derivatives of LL-37/hCAP-18 blunts
the clinical consequences of septic shock in animal models. These effects
are mediated by binding of the cationic peptide antibiotics to endotoxin,
neutralizing LPS and decreasing the release of TNF-α (Kirikae T. et al.,
1998). Evidence that mammalian antimicrobial peptides actually contribute to
innate immunity in vivo is based primarily on their expression patterns and in
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vitro activity against microorganisms. In vitro, naturally occurring cationic
peptides, as well as synthetic analogues block the ability of LPS to stimulate
the production of TNF-, IL-6, and other inflammatory mediators. Moreover,
studies in mice have shown that cationic peptides can block endotoxin-
induced TNF- release and reduce the mortality associated with
endotoxemia (Kirikae T. et al., 1998; Scott M.G. et al., 1999; VanderMeer
T.J. et al., 1995). However, several cationic peptides have been shown to
bind LPS (Scott M.G. et al., 2000).
Although cationic peptides often have antimicrobial activity, the key to
their therapeutic potential may lie among the other activities attributed to
them, such as their ability to alter the inflammatory response (Scott M.G. et
al., 2000a). For example, under conditions analogous to those found in vivo,
LL-37 is a weak antimicrobial agent. Conversely, it is one of the most potent
anti-endotoxic agents among cationic host defense peptides, is directly
chemotactic, and induces dramatic changes in the phenotype of monocyte-
derived dendritic cells. This indicates a substantial role of cationic peptides
in the innate immune response (Scott M.G. et al., 2002).
In a study by De Yang et al. (De Y. et al., 2000), LL-37 was
demonstrated to be a chemoattractant for monocytes, neutrophils, and T
cells.
In the light of these observations, we investigated the therapeutic
potential in our rat PCI model, applying LL-37 once versus three times iv and
in a prophylactic versus therapeutic approach. In the PCI model septic shock
was induced by intraperitoneal administration of a standardized stool
suspension (MIX 5). The PCI model combined with the CMRT concept
represents a clinic relevant experimental setting superior to other more
simple models like models with single strain bacteria or endotoxemia. In our
trials the clinical situation and conditions of randomized controlled trials (for
e.g. randomization, blinding, adequate statistics) are modeled (Bauhofer A. et
al., 2004; Lorenz W. et al., 1994; Torossian A. et al., 2003). The antimicrobial
and endotoxin-neutralizing effects of LL-37 were used in combination with
clinically common iv antibiotics.
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Our findings clearly show that LL-37 reduces the PCI mediated adverse
effects, by down regulation of the pro-inflammatory cytokines response. The
pro-inflammatory reaction in the PCI model is most probably induced by
microbial compounds like LPS and lipoteichoic acid. In all of the APM studies
LL-37 caused inhibition of TNF-α, IL-1 and MIP-2 production in blood.
Importantly, intravenous LL-37 produced a significant reduction in TNF-α
plasma levels, compared to the control group treated just with standard
antibiotics as described before. Antibiotic therapy and LL-37 reduced the
plasma levels of LPS to a similar extent and showed similar abilities in
blocking TNF-α levels in animals. It is important to notice that prophylactic
administration of LL-37 was not as effective with regard to improved survival
rate as was therapeutic administration (1x, one hour after contamination).
Two key determinants of sepsis survival are bacterial clearance and the
inflammatory response to the infection. Inflammatory response to the
infection was reduced as demonstrated by pro-inflammatory cytokines.
Finally, comparable data were observed when the drugs were administered
at 60 minutes after PCI.
The protective effect of LL-37 on animal survival is likely due to both, the
ability of this peptide to decrease the levels of endotoxin and pro-
inflammatory cytokines in the plasma of septic animals and its bactericidal
activity. Additional mechanisms by which LL-37 contributes to host defenses
against microbial invasion have been previously described.
We found in our trial that LL-37 prophylaxis 12 hours before infection is
not effective, but LL-37 therapy improves survival after sepsis significantly.
This is in accordance with the results of a recent study, which demonstrated
improved survival after CLP-induced sepsis with LL-37 treatment being
superior to conventional antibiotic treatment (Cirioni O. et al., 2006).
However, our results extend these findings, in that we routinely use
antibiotics in our intra-abdominal sepsis model. This suggests additive or
even synergistic effects of antibiotics (cefuroxime/metronidazole) in
combination with LL-37. Though the mechanism of interaction needs further
investigation. Antibiotics are routinely given for sepsis prophylaxis in clinical
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practice and may interact differentially with any other mediator such as
cytokines (Bauhofer A. et al., 2004)
The data presented in our study support the notion that prophylactically
or therapeutically administration of LL-37 in our PCI model provides
protection against bacterial pathogens, such as against peritoneal infection
and contamination (PCI). Bals et al. showed that this supports the suggested
role of LL-37/hCAP-18 as a host defense molecule activating phagocytes in
epithelia and the blood. (Bals R. et al., 1999b)
Thus, it is becoming increasingly clear that peptides are more than
simply naturally occurring antibiotics, but, rather, play a complex role in
resolving infection, attenuating inflammation, and, when this attempt at
resolution is not sufficient, alerting the adaptive immune response (Bowdish
D.M. et al., 2004). Characterization of the mechanism of action of these
peptides is shedding light on the properties that make them potentially
therapeutic agents.
It is worth considering what would permit one to conclusively test the
alternative hypotheses whether, e.g., LL-37 is acting as an immune
modulator or an antimicrobial in vivo. It was shown that a derivative of LL-37,
instilled simultaneously with P. aeruginosa into the mouse lung, reduced lung
damage and pro-inflammatory cytokine production but not bacterial counts
(Scott M.G. et al., 1999a). In an analogous manner, it is well-established that
LL-37 treatment can reverse endotoxemia, even in the absence of infection.
Therefore, we consider that the general thesis that LL-37 can act as an
immunomodulating factor is well established. What is not clear yet is which
function of LL-37 dominates in clearing an infection. In conclusion, our study
data demonstrate the potential for the therapeutic use of immuno-modulatory,
anti-infective peptides, which do not eliminate bacteria directly and therefore,
circumvent the issue of antimicrobial resistance (Bowdish D.M. et al., 2005).
These agents should find broad use in a variety of modes of administration
and treatment regimes and against a range of pathogens.
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Conclusion: LL-37 is a multifunctional peptide displaying both
antimicrobial activity and a variety of immunological functions related to
inflammation, suggesting that LL-37 may regulate both infection and
inflammation. Therefore, LL-37 may form a template for the development of
new anti-infectious agents. Development of LL-37-based therapies should
however, consider the balance between antimicrobial and inflammatory
activities. Whether such peptides enhance wound repair, and thus may act
as dual agents, is of great importance, but remains to be determined.
The data presented in this study provide evidence that antimicrobial
peptides protect against the consequences of bacterial infection (PCI -
sepsis), highlighting the role of these substances as part of the innate host
defense system. The protective effect resulting from LL-37 immunity
modulation suggests new strategies for developing treatment of infections
and favorably modifying the host response.
Thus, LL-37 could be an attractive candidate as a therapeutic agent that
can be used for endotoxin shock and sepsis caused by gram-negative and
gram-positive bacterial infections.
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5.2. Hyperthermia – a beneficial factor in sepsis?
Animal and human studies have shown that intraoperative hypothermia
increases the risk of wound infection (Kurz A. et al., 1996; Sheffield C.W. et
al., 1994). Intraoperative hypothermia is likely to cause a reduction in
peripheral circulation, which may increase tissue hypoxia and thus makes the
wound more susceptible to infection, even if contamination levels are low.
The process of warming using a warm air blanket, to prevent hypothermia, is
becoming common practice for most major surgical procedures.
The exogenous application of heat stress triggers a natural cellular
defense mechanism called the stress response. In previous studies (Ribeiro
S.P. et al., 1994; Villar J. et al., 1993; Villar J. et al., 1994), it has been
demonstrated that the stress response is protective when induced 18 hours
before intratracheal instillation of phospholipase A2 and before the production
of experimental sepsis by caecal ligation and perforation (Chu E.K. et al.,
1997).
The evolutionarily conserved febrile response during infection has been
associated with improved survival in vertebrates and invertebrates although
its protective mechanism of action and especially that of the thermal
component is one of the most poorly understood aspects of inflammation -
much of the hyperthermia effects on the immune system have been
attributed to the expression of heat shock proteins in several organs, as
shown for example after the hyperthermia treatment of mice (39-40°C over 6
hours) (Ostberg J.R. et al., 2005). In our setting 24 hours after hyperthermia
pretreatment (41°C) we could not detect increased HSP levels. Probably the
duration of heat application of only one hour was not long enough, but the
current results demonstrate that preconditioning hyperthermia was
associated with increased survival after experimental sepsis (PCI). We did
not measure or control glutamine levels in our animals; however it has been
shown recently that glutamine-starving monocytes have a reduced thermo-
resistance. This is associated with an inhibition of the cytoprotective protein
HSP70 in vitro (Pollheimer J. et al., 2005) - temperatures within the range of
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physiologic fever influence production or bioactivity of pro-inflammatory
cytokines (Blake D. et al., 1994) In addition, apoptosis induced by sepsis-is
attenuated (Chen H.W. et al., 2000); - lipopolysaccharide induced
hyporesponsiveness of platelets is reduced (Dong H.P. et al., 2005). Fever-
range thermal stress promotes lymphocyte-endothelial adhesion, which also
suppresses tumor progression (Chen Q. et al., 2006). Metabolic amelioration
of lactic acidemia in a rat model of sepsis, possibly preserves organ
perfusion, improves oxygen delivery and prevents cellular dysfunction
(Deshpande G.G. et al., 2000). Accumulating evidence indicates that
hyperthermia specifically enhances polymorphonuclear neutrophils (PMNs).
PMNs are recognized as key mediators of inflammation, and may also play a
crucial role in mediating the anti-tumor effects of a mild, fever-range whole
body hyperthermia (Ostberg J.R. et al., 2005). Thus, therapeutic use of mild
(fever-range) whole body hyperthermia (39-40°C) was first reported to be
beneficial in a phase I study for patients with advanced solid tumors (Kraybill
W.G. et al., 2002). However, although there is strong evidence in animal
models of infection supporting therapeutic use of hyperthermia, only a few
prospective, randomized trials have been reported in humans. These
basically focus on metastases tumor therapy, and the results remain
equivocal, with mild to moderate hyperthermia as an adjunctive to radio-
/chemotherapy providing substantial benefit, for example in a phase II study
in 41 patients with metastatic colon cancer (Hegewisch-Becker S. et al.,
2002) and in 16 patients with advanced gastric carcinoma (De Roover A. et
al., 2006). However, major clinical trials of therapeutic hyperthermia or
hyperthermic preconditioning in a curative approach are lacking to date.
Interestingly, timing of hyperthermia treatment in relation to an infectious
insult seems to be a crucial factor: like others before (Gulluoglu B.M. et al.,
2002; Hotchkiss R. et al., 1993; Koh Y. et al., 1999; Villar J. et al., 1994), we
found an improved (though not significant) survival rate 120 hours after intra-
abdominal sepsis in animals with hyperthermic preconditioning (41°C for 1 h)
which per se could not increase the outcome after sepsis significantly (P =
0.1). So far, timing of hyperthermia may also be of importance, since in one
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recent report hyperthermia treatment after sepsis was found to be
unfavorable (L'Her E. et al., 2006).
Whether the observed benefits on survival duration are due to potential
impacts for energy metabolism or to an anti-inflammatory effect of
hyperthermia requires further investigation.
Besides, preoperative warming may be an alternative to the controversial
use of prophylactic antibiotics, which avoids the associated risks of allergy
and resistance, in clean surgery (Gulluoglu B.M. et al., 2002).
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5.3. Additive effects of the antimicrobial peptide LL-37
and hyperthermia in sepsis
In our main trial, neither hyperthermia preconditioning nor LL-37 per se
could increase the survival rate after sepsis significant compared to control,
but the combination of both modalities revealed additive effects resulting in
an improved outcome. The combination was effective as compared with
controls (P = 0.001) and with hyperthermic preconditioning alone (P = 0.02),
suggesting additive effects. The markedly reduced pro-inflammatory
cytokines may have contributed to this. Reduced pro-inflammatory cytokine
levels after LL-37 treatment and sepsis have also been reported by others
(Cirioni O. et al., 2006a). Hence both modalities may stimulate cellular
immune defense mechanisms and alter the cytokine network in our combined
trial. LL-37 amplified the beneficial effect of hyperthermic preconditioning on
survival and reduced the excessive pro-inflammatory cytokine production, but
not beyond that of septic control rats. This is important, since a reduction
below the levels in the control animals would be adverse for infection
clearance. An adequate immune response is needed. Hyperthermia per se is
known to alter innate and adaptive immunity; therefore it was unreasonable
to examine a hyperthermic preconditioning only group.
A potential explanation for the increased survival after hyperthermia plus
LL-37 treatment in sepsis is a reduction of the excessive release of the pro-
inflammatory cytokine IL-6 and the chemokine MIP-2. MIP-2 enhances PMN
recruitment and migration into infected tissues. In this light we can affirm
enhanced neutrophil function through hyperthermic preconditioning. Our
model is clinically relevant for studying development of postoperative intra-
abdominal sepsis and accompanying prophylaxis and treatments. Thus
current and previous work indicates that hyperthermic preconditioning may
improve host immune response to a subsequent infectious challenge.
Furthermore, our results suggest, that administration of LL-37 or its active
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motifs, may improve host response to bacterial peritonitis in such patients,
however more data on the mechanisms and possible side-effects are needed
before it may enter a clinical trial in septic patients. These results of this work
are published in Anesthesiology. (Torossian A. et al., 2007).
Conclusion: Our model is clinically relevant for studying the development
of postoperative intraabdominal sepsis and accompanying risk factors. This
work indicates that postoperative hyperthermia enhances the host immune
response to an anti-infectious challenge. Our results suggest that the
administration of LL-37 in combination with hyperthermia preconditioning
(heat shock or prewarming) may improve the host response to bacterial
peritonitis in patients at risk.
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6. Summary
Background: We studied the effects of LL-37 prophylaxis or therapy on
the outcome after intra-abdominal sepsis and tested whether additional
preconditioning with fever-range hyperthermia augments host immune
response and improves survival.
Methods: A rat model of peritoneal contamination and infection (PCI)
with human stool bacteria was used to simulate clinical trial conditions. In
Trial 1 we compared 1 ) PCI only; 2 ) LL-37 prophylaxis (0.5 mg/kg, 12 h
before infection) and 3 ) LL-37 therapy 3 time administration (0.5 mg/kg, -12h
before PCI and +12h, +36h after infection), 20 rats/group. In Trial 2 we
compared 1 ) PCI only; 2 ) LL-37 prophylaxis (0.5 mg/kg, 12 h before
infection) and 3 ) LL-37 therapy (0.5 mg/kg, 1h after infection), 20 rats/group.
In Trial 3, using 22 rats/group, we compared 1 ) PCI only; 2 ) LL-37 therapy;
3 ) hyperthermic preconditioning (41°C for 1h, 24 h before infection); and 4 )
hyperthermia combined with LL-37 therapy (0.5 mg/kg). The primary
endpoint was mortality at 120 h. Secondary endpoints were systemic pro-
inflammatory cytokine (TNF-α, IL-6, MIP-2) and heat shock protein (HSP)-70
levels.
Results: In Trial 1 we achieved a survival rate of 40% in the control
group. In the group with the antimicrobial protein LL-37 administrated once at
-12h, before inoculum survival was increased to 70% and to 67% in the
group with LL-37 administrated three times (at time point correspondingly to -
12h; +12h; +36h in relation to PCI. In both groups survival rates were not
significant different to the control. In Trial 2, 30% of the control group
compared to 70% of the LL-37 therapy group survived (P=0.038). After LL-37
prophylaxis survival was 55%. Survival rate in trial 3 was 38% in the control
group, 67% in the LL-37 therapy group, 59% in the hyperthermia
preconditioning group and 90% in the combination group (hyperthermia
preconditioned plus LL-37 therapy) (P = 0.01). Hyperthermic preconditioning
83
plus LL-37 reduced pro-inflammatory cytokine concentrations after sepsis.
Compared to controls MIP-2 levels were 1.5  1.5 pg/ml versus 11  6 pg/ml,
(P = 0.028) and IL-6 levels were respectively 13  8 pg/ml versus 86  31
pg/ml, (P = 0.015).
Conclusions: In this rat model of intra-abdominal sepsis, LL-37 therapy
given alone was more effective in comparison to LL-37 given three times.
The later was not successful to improve the outcome significantly. The
combination preconditioning and LL-37 therapy was most effective.
Additional hyperthermia, initiated 24 hours before contamination, reduced
mortality and downgraded the systemic pro-inflammatory cytokine response.
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Zusammenfassung
Antimikrobielle Peptide (AMP) sind Bestandteil des angeborenen
Immunsystems. Wir haben die Wirkung des antimikrobiellen Peptids – LL-37
als Prophylaxe oder Therapie in Kombination mit hyperthermer
Präkonditionierung in septischen Ratten erforscht. Wir untersuchten wieweit
die oben beschriebenen Behandlungen die Mortalität septischer Ratten senkt
und die Freisetzung pro-inflammatorischer Zytokine reduziert.
Methodik: Wir verwendeten für die Studien das CMRT Konzept (clinic
modelling randomised trials) in Ratten, um die komplexe klinische Situation
und die Bedingen von klinischen Studien zu simulieren. In dem von uns
verwendeten Peritonitismodell wurden die Tiere in Fentanyl/ DHB-Analgesie,
nach i.v. Antibiotikaprophylaxe laparotomiert und mit einer standardisierten
humanen Stuhlsuspension peritoneal kontaminiert und infiziert (PCI). In
Studie I erhielten die Tiere 1) PCI (Kontrolle); 2) eine Prophylaxe mit 0,5
mg/kg von dem antimikrobiellen Peptid LL-37 (12 h vor PCI), 3) 3x LL-37 (12
h vor -; 12h nach- und 36 h nach PCI); 20 Ratten/Gruppe. In Studie II
erhielten sie 1) eine PCI (Kontrolle); 2) eine Prophylaxe mit 0,5 mg/kg LL-37
(12 h vor PCI), 3) eine Therapie mit 0,5 mg/kg LL-37 (eine Stunde nach PCI);
20 Ratten/Gruppe. In Studie III erhielten die Tiere 1) eine PCI (Kontrolle); 2)
eine Therapie mit 0,5 mg/kg LL-37 (eine Stunde nach PCI); 3) eine
hypertherme Präkonditionierung (41°C für 1h, mit 24 h vor PCI) und 4)
Therapie mit 0,5 mg/kg LL-37 (eine Stunde nach PCI) in Kombination mit
hyperthermische Präkonditionierung (41°C für 1h, mit 24 h vor PCI), 22
Ratten/Gruppe. Der primäre Endpunkt war in allen Studien die 120-Stunden-
Überlebensrate; in Studie II und III wurden als sekundäre Endpunkte die
Plasmaspiegel von pro-inflammatorischen Zytokinen (TNF-α. IL-6 und MIP 2)
und von HSP70 (heat shock protein) bestimmt.
Ergebnisse: In Studie I überlebten in der Kontrollgruppe 40%, mit LL-37
Prophylaxe (-12h LL vor PCI) 70% und nach LL-37 3x (LL 3x) 67%. In Studie
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II betrug die Überlebensrate in der Kontrollgruppe 30%, nach LL-37
Prophylaxe (-12h AMP 1x) 55%, und nach LL-37 Therapie (+1h AMP 1x)
70% (p=0,038, vs. Kontrolle). In Studie III betrug die Überlebensrate in der
Kontrollgruppe 38%, nach LL-37 Therapie (+1h AMP 1x) 67%, nach
hyperthermische Präkonditionierung (41°C für 1h, mit 24 h vor PCI) 59%. Nur
durch Kombination der LL-37 Therapie (0,5 mg/kg LL-37 eine Stunde nach
PCI) mit der hyperthermischen Präkonditionierung (41°C für 1h, 24 h vor
PCI) konnte die Überlebensrate signifikant (P = 0,01) auf 90% erhöht
werden. Die untersuchten Zytokine konnten durch die LL-37 Therapie und
am deutlichsten durch Kombination von LL-37 mit der hypethermen
Präkonditionierung gesenkt werden. Der statistische Vergleich zwischen der
Kontrollgruppe und der Kombinationsbehandlung ergab einen signifikanten
Unterschied für MIP-2 mit P = 0,028 und für IL-6 mit P = 0,015.
Schlussfolgerung: Die besten Ergebnisse in Form einer gesteigerten
Überlebensrate erbrachte in unserem Sepsismodell eine antimikrobielle
Therapie mit LL-37 in Kombination mit einer hyperthermen
Präkonditionierung. Eine LL-37 Prophylaxe, eine 3-malige Gabe von LL-37
(vor und nach Sepsisinduktion) oder eine alleinige hypertherme
Präkonditionierung konnte nicht im gleichen Umfang das Outcome
verbessern. Ein möglicher Erklärungsgrund für die positive Wirkung der
Kombination von LL-37 und Hyperthermie könnte in der Erniedrigung von




A fost studiat efectul administrării adiţionale a LL-37 la terapia
antimicrobiana uzuală (cefuroxime şi metronidazole) în infecţia
intraperitoneală, provocată prin inocularea de masă fecală standardizată la
şobolani Wistar (masculi). Proteina antimicrobiană din grupa Cathelicidinelor
a fost administrată intravenos cu scop de profilaxie şi terapie. În studiu au
fost incluse şi grupe de animale la care s-a utilizat precondiţionarea termică
(supunerea în prealabil la hipertermie). Scopul studiului a constat în
evaluarea influenţei terapiei adiţionale cu proteina antimicrobiană LL-37
asupra ratei de supravieţuire a animalelor, timp de 120 ore după provocarea
infecţiei intraperitoneale şi monitorizarea răspunsului imun al organismului.
Metode. Pentru simularea condiţiilor clinice a fost utilizat modelul deja
cunoscut ca CMRT sau şobolan infectat şi contaminat intraperitoneal (ICI) cu
mase fecale umane preventiv standardizate. Primul şir de experimente a
inclus trei grupe a câte 20 animale fiecare. La prima grupă (de control) s-a
efectuat tratament uzual după (ICI). La animalele incluse în grupa a doua li s-
a administrat cu scop profilactic proteina antimicrobiană LL-37 (0,5 mg/kg) cu
12 ore înainte de infectare, iar animalelor din grupa a treia proteina LL-37
(0,5mg/kg) li s-a administrat atât profilactic cu 12 ore înainte de ICI cât şi
terapeutic, peste 12 şi 36 ore.
În al doilea şir de experimente au fost incluse trei grupe omogene a câte
20 animale fiecare. Prima grupă (de control) a primit tratament uzual după
ICI. Animalelor din grupa a doua li s-a administrat cu scop profilactic LL-37
(0,5 mg/kg) cu 12 ore înainte de infectare. Animalele din grupa a treia au
primit tratament adiţional cu LL-37 (0,5 mg/kg) la interval de o ora după
infectare.
În şirul al treilea de experimente au fost incluse patru grupe omogene a
câte 21 animale fiecare. Grupa întâia a fost ca de obicei cea de control.
Animalele din grupa a doua au primit tratament adiţional cu LL-37 (0,5
mg/kg) peste o ora după infectare. Animalele din grupa a treia au fost supuse
precondiţionării termice (hipertermie T=+41°C, timp de o oră) cu 24 ore
înainte de ICI. Animalele din grupa a patra au fost supuse unui tratament
combinat, care a inclus precondiţionarea termica (similar grupei a treia) şi
administrare terapeutică adiţională a LL-37 (0,5 mg/kg) la o oră după
infectare.
A fost evaluată supravieţuirea animalelor timp de 120 ore de la ICI.
Pentru evaluarea răspunsului organismului la infecţie şi efectul
tratamentului aplicat, a fost determinată evoluţia concentraţiei citokinelor
proinflamatorii (TNF-α, IL-6), chemokinei MIP-2 şi nivelul HSP-70 (heat
shock protein) în sângele animalelor.
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Rezultate. În primul şir de experimente în grupul de control s-a observat
o rată de supravieţuire a animalelor de 40%, în grupa a doua rata de
supravieţuire a fost 70%, iar în grupa a treia – 67%. Indicii obţinuţi în grupele
doi şi trei nu sunt statistic semnificativi comparativ cu grupa de control. În
şirul doi de experimente s-a observat o rata variabilă de supravieţuire de
30% - în grupa de control, 55% - în grupa a doua cu administrare profilactică
a LL-37 şi 70% - în grupa a treia cu administrarea terapeutica a LL-37.
Rezultatul obţinut în grupa a treia este relevant şi statistic semnificativ
(P=0,038) în comparaţie cu grupa de control.
Şi în şirul al treilea de experimente rata supravieţuirii animalelor a fost
diferită în dependenţă de metoda de terapie adiţională utilizată. În grupa de
control au supravieţuit 38% animale, în grupa cu administrare terapeutică a
LL-37 au supravieţuit 67% animale, în grupa a treia unde s-a folosit
precondiţionarea termică a animalelor au supravieţuit 59% , iar cel mai
surprinzător rezultat a fost obţinut în grupa a patra unde a fost aplicată
terapia suplimentară combinată, unde au supravieţuit 90% animale, rezultat
cu o veridicitate statistică înaltă de 95% sau P=0,01. Aproape toate metodele
utilizate în tratamentul sepsisului au contribuit nesemnificativ la diminuarea
concentraţiei citokinelor proinflamatorii. Precondiţionarea hipertermică şi
administrarea terapeutică a LL-37 a contribuit la diminuarea semnificativă a
concentraţiei citokinelor proinflamatorii după declanşarea sepsisului. Astfel
concentraţia citokinelor animalelor aflate în stare septică a fost: MIP-2 11±6
pg/ml VS 1,5 ±1,5 pg/ml (cu semnificaţia statistică P=0,028); IL-6 86±31
pg/ml VS 13±8 pg/ml (cu semnificaţia statistică P=0,015), unde prima valoare
corespunde grupei de control, iar a doua valoare grupei cu tratament
adiţional combinat.
Concluzii. În această modelare a sepsisului intra-abdominal
supravieţuirea animalelor a fost mai înaltă în grupele cu administrare
terapeutică a LL-37 într-o singură priză, şi mai scăzută în grupa cu
administrare a LL-37 în trei prize. Dar cel mai impresionant rezultat de
supravieţuire maximală a fost obţinut în grupa unde s-a utilizat tratamentul
adiţional combinat care include precondiţionarea hipertermică şi
administrarea terapeutică a LL-37 într-o singură priză. Tratamentul adiţional
combinat a contribuit la reducerea semnificativă a răspunsului proinflamator
al citokinelor, micşorând esenţial concentraţia lor plasmatică, în aşa mod,
contribuind la o scădere importantă a ratei mortalităţii. Administrarea
profilactică a LL-37 nu a adus careva rezultate importante.
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8. Annex
8.1. List of abbreviation
ACCP The American College of chest Physicians
ARDS adult respiratory distress syndrome
CARS compensatory anti-inflammatory response syndrome
CD14 cluster of differentiation group of cell surface marker protein; a
membrane-associated glycosylphosphatidylinositol-linked
protein expressed at the surface of cells, especially
macrophages
CMRT clinic modeling randomized trials
CO2 bicarbonate
CRAMP cathelin related antimicrobial peptide
CRP C-reactive protein
DNA Deoxyribonucleic acid
G-CSF granulocyte colony-stimulating factor
hCAP-18 human cationic antimicrobial peptide of 18 kDa
HLA-DR human leukocyte antigen-DR
HSP70 70-kDa heat shock protein
HSP heat-shock protein
HSR heat shock response








LD100 lethal dose 100 percent
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LD50 median lethal dose
LL-37 a peptide which begins with two leucine residues containing 37
amino acid residues
LODS logistic organ dysfunction system
LOS length of stay
LPS bacterial lipopolysaccharides
LRR leucin-rich-repeats
MCP monocytes chemoattractant protein
MIP macrophage inflammatory protein
MODS multiple organ dysfunction syndrome
NK cells natural killer cells
OP Operation
PAF platelet-activating factor
PCI peritoneal contamination and infection
PCT procalcitonin
PELOD pediatric logistic organ dysfunction
PEMOD pediatric multiple organ dysfunction
PGE2 prostaglandin
PIRO Predisposing, Infection, Response, Organ
s.c. Subcutaneous
SCCM Society of Critical Care Medicine
SEM standard error of the mean
SepNet Competence Network Sepsis
SIRS Systemic Inflammatory Response Syndrome
SOFA sepsis-related organ failure assessment
TIR Toll/IL-1-receptor domain
TLR Toll-like receptor
TLR9 Toll-like receptor 9
TLR4 Toll-like receptor 4
TNF-α Tumor necrosis factor α
TMN Classification by tumor, metastasis, lymph nod
US United States
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